INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50501, 18915, 'Estradiol', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50502, 18916, 'Estradiol', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50503, 4438, 'Estradiol', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50504, 5083, 'Estradiol', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50505, 8063, 'Estradiol', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50506, 18914, 'Estradiol', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50507, 18915, 'Estradiol', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50508, 18916, 'Estradiol', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50509, 4438, 'Estradiol', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50510, 5083, 'Estradiol', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50511, 8063, 'Estradiol', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50512, 18914, 'Estradiol', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50513, 18915, 'Estradiol', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50514, 18916, 'Estradiol', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50515, 1075, 'Amiloride', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50516, 20503, 'Amiloride', 'Acidosis', 'Acidosis alters the ratio of extracellular to intracellular potassium and may commonly lead to rapid increases in serum potassium levels.  Conversely, high serum potassium concentrations may potentiate acidosis.  Because of their hyperkalemic effects, therapy with potassium-sparing diuretics should be avoided in patients with metabolic or respiratory acidosis.  These agents should be used cautiously in patients in whom acidosis may occur, such as patients with cardiopulmonary disease, severe respiratory disease, or poorly controlled diabetes.  Acid-base balance and serum potassium levels should be monitored at regular intervals.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Gabow PA, Moore S, Schrier RW "Spironolactone-induced hyperchloremic acidosis in cirrhosis." Ann Intern Med 90 (1979):  338-40|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50517, 1075, 'Amiloride', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50518, 20503, 'Amiloride', 'Diabetes Mellitus', 'Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with diabetes mellitus, with or without nephropathy, may be particularly susceptible to the hyperkalemic effect of these drugs due to a defect in the renin-angiotensin-aldosterone axis.  Therapy with potassium-sparing diuretics should be avoided, if possible, in patients with diabetes, especially uncontrolled or insulin-dependent diabetes mellitus.  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Amery A, Berthaux P, Bulpitt C, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F, Hellemans J, Lund-Johansen PMutsers A, Tuomilehto J "Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly." Lancet 1 (1978):  681-3|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Jariwalla AG, Jones CR, Lever A, Hall R "Spironolactone and diabetic ketoacidosis." Postgrad Med J 57 (1981):  573-4|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50519, 1075, 'Amiloride', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50520, 20503, 'Amiloride', 'Water-Electrolyte Imbalance', 'All diuretics may cause or aggravate fluid and electrolyte disturbances.  Potassium-sparing diuretics may cause hyperkalemia and, infrequently, hyponatremia.  The latter generally occurs when these agents are combined with other diuretics such as thiazides or used in markedly edematous patients with restricted sodium intake.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with or predisposed to electrolyte abnormalities.  Electrolyte imbalances should be corrected prior to initiating therapy, and serum electrolyte concentrations should be monitored periodically and maintained at normal ranges during therapy.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Tarssanen L, Huikko M, Rossi M "Amiloride-induced hyponatremia." Acta Med Scand 208 (1980):  491-4|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Roberts CJ, Channer KS, Bungay D "Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene." Br Med J (Clin Res Ed) 288 (1984):  1962|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Hirschl MM, Seidler D, Laggner AN "Spironolactone-associated hyponatremic coma." Nephron 67 (1994):  503', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50521, 1075, 'Amiloride', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50522, 20503, 'Amiloride', 'Hyperkalemia', 'The use of potassium-sparing diuretics is contraindicated in the presence of elevated serum potassium concentrations (> 5.5 mEq/L).  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Careful monitoring of serum potassium levels is necessary in all patients treated with potassium-sparing diuretics, especially during initiation of therapy, after dosage adjustment, and during illness that could alter renal function.  The diuretic should be withdrawn immediately if hyperkalemia develops, and measures should be initiated to lower serum potassium if it exceeds 6.5 mEq/L.  The combined use of a potassium-sparing diuretic with a kaliuretic diuretic (e.g., thiazides) may decrease the risk of hyperkalemia.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970):  58-70|Davidson C, Burkinshaw L, Morgan DB "The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure." Postgrad Med J 54 (1978):  405-9|Maddox RW, Arnold WS, Dewell WM "Extreme hyperkalemia associated with amiloride ." South Med J 78 (1985):  365|Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI "Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects." Br J Clin Pharmacol 18 (1984):  369-75|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Cohen AB "Hyperkalemic effects of triamterene." Ann Intern Med 65 (1966):  521-7|Hollenberg NK, Mickiewicz C "Hyperkalemia in diabetes mellitus. Effect of a triamterene- hydrochlorothiazide combination." Arch Intern Med 149 (1989):  1327-30|Hansen KB, Bender AD "Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination." Clin Pharmacol Ther 8 (1967):  392-9|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|Walker BR, Capuzzi DM, Alexander F, Familiar RG, Hoppe RC "Hyperkalemia after triamterene in diabetic patients." Clin Pharmacol Ther 13 (1972):  643-51|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Ochs HR, Greenblatt DJ, Bodem G, Smith TW "Spironolactone." Am Heart J 96 (1978):  389-400|Feinfeld DA, Carvounis CP "Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment." JAMA 240 (1978):  1516|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Udezue EO, Harrold BP "Hyperkalaemic paralysis due to spironolactone." Postgrad Med J 56 (1980):  254-5|Brest AN "Spironolactone in the treatment of hypertension: a review." Clin Ther 8 (1986):  568-85|Jeunemaitre X, Dreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P, Menard J, Corvol P "Long-term experience of spironolactone in essential hypertension." Kidney Int 34 Suppl (1988):  s14-7|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006):  49-58', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50523, 1075, 'Amiloride', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50524, 20503, 'Amiloride', 'Liver Diseases', 'Rapid alterations in fluid and electrolyte balance may precipitate hepatic coma in patients with liver disease.  Hepatic encephalopathy has been associated with the use of diuretics, most frequently thiazides but also some potassium-sparing diuretics.  Therapy with all diuretics should be administered cautiously in patients with severely impaired hepatic function.  These patients should be monitored carefully for signs and symptoms of hepatic encephalopathy such as tremors, confusion, increased jaundice, and coma.  Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment.', '3', 'Karim A, Zagarella J, Hribar J, Dooley M "Spironolactone I: disposition and metabolism." Clin Pharmacol Ther 19 (1976):  158-69|Sadee W, Schroder R, Leitner E, Dagcioglu M "Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure." Eur J Clin Pharmacol 7 (1974):  195-200|Villeneuve JP, Rocheleau F, Raymond G "Triamterene kinetics and dynamics in cirrhosis." Clin Pharmacol Ther 35 (1984):  831-7|Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD "Pharmacokinetics of triamterene." Clin Exp Hypertens A 5 (1983):  249-69|Dao MT, Villeneuve JP "Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis." Clin Invest Med 11 (1988):  6-9|Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites." Gastroenterology 102 (1992):  1680-5|Abshagen U, Rennekamp H, Luszpinski G "Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment." Eur J Clin Pharmacol 11 (1977):  169-76|Overdiek HW, Merkus FW "The metabolism and biopharmaceutics of spironolactone in man." Rev Drug Metab Drug Interact 5 (1987):  273-302|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):|Renkes P, Gaucher P, Trechot P "Spironolactone and hepatic toxicity." JAMA 273 (1995):  376-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50525, 1075, 'Amiloride', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50526, 20503, 'Amiloride', 'Kidney Diseases', 'The use of potassium-sparing diuretics is contraindicated in patients with anuria, acute or progressive renal insufficiency, or diabetic nephropathy.  Potassium-sparing diuretics can cause hyperkalemia, which may result in life-threatening cardiac arrhythmias.  Patients with impaired renal function may be particularly susceptible to the hyperkalemic effect of these drugs.  Therapy with potassium-sparing diuretics should be administered cautiously in patients with evidence of renal function impairment (BUN > 30 mg/dL or serum creatinine > 1.5 mg/dL).  If these drugs are used, serum potassium levels and renal function should be monitored at regular intervals.  Determination of serum electrolytes is especially important during initiation of therapy, after a dosage adjustment, and during illness that could alter renal function.', '3', 'Vidt DG "Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic." Pharmacotherapy 1 (1981):  179-86|Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J "Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients." Clin Pharmacol Ther 34 (1983):  448-53|Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI "Renal failure with potassium-sparing diuretics." N Z Med J 98 (1985):  629-33|George CF "Amiloride handling in renal failure." Br J Clin Pharmacol 9 (1980):  94-5|Somogyi A, Hewson D, Muirhead M, Bochner F "Amiloride disposition in geriatric patients: importance of renal function." Br J Clin Pharmacol 29 (1990):  1-8|Knauf H, Reuter K, Mutschler E "Limitation on the use of amiloride in early renal failure." Eur J Clin Pharmacol 28 (1985):  61-6|Schiffl H, Schollmeyer P "Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension." Int J Clin Pharmacol Ther Toxicol 23 (1985):  585-8|Hollenberg NK, Mickiewicz CW "Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide) [published erratum appears in Am J Cardiol 1990 Aug 1;66(3):388]." Am J Cardiol 63 (1989):  b37-41|"Triamterene and the kidney." Lancet 1 (1986):  424|Roy LF, Villeneuve JP, Dumont A, Dufresne LR, Duran MA, Morin C, Jobin J "Irreversible renal failure associated with triamterene." Am J Nephrol 11 (1991):  486-8|"Product Information. Dyrenium (triamterene)." SmithKline Beecham  (2001):|Yap V, Patel A, Thomsen J "Hyperkalemia with cardiac arrhythmia. Induction by salt substitutes, spironolactone, and azotemia." JAMA 236 (1976):  2775-6|Neale TJ, Lynn KL, Bailey RR "Spironolactone-associated aggravation of renal functional impairment." N Z Med J 83 (1976):  147-9|"Product Information. Midamor (amiloride)." Merck & Co., Inc  (2001):|"Product Information. Aldactone (spironolactone)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50527, 5485, 'Estrone sulfate', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', 'Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979):  123|Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981):  497-506|Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986):  434-41|Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989):  147-51|Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979):  9-13|Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977):  570-1|Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985):  969-72|Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977):  385-9|Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994):  1213-23|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996):  370-5|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50528, 13001, 'Estrone sulfate', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', 'Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979):  123|Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981):  497-506|Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986):  434-41|Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989):  147-51|Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979):  9-13|Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977):  570-1|Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985):  969-72|Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977):  385-9|Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994):  1213-23|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996):  370-5|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50529, 13002, 'Estrone sulfate', 'Uterine Hemorrhage', 'The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding.  Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma.  The risk may be offset substantially by the addition of a progestin but may not be completely abolished.  Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy.  The same applies if recurrent or persistent bleeding develops during estrogen therapy.', '3', 'Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979):  123|Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981):  497-506|Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986):  434-41|Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989):  147-51|Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979):  9-13|Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977):  570-1|Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985):  969-72|Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977):  385-9|Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994):  1213-23|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996):  370-5|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50530, 5485, 'Estrone sulfate', 'Breast Neoplasms', 'The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation.  High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.', '3', 'Ewertz M "Oral contraceptives and breast cancer risk in Denmark." Eur J Cancer 28A (1992):  1176-81|Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979):  123|Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol 134 (1991):  1386-95|Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol 134 (1991):  1375-85|Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981):  497-506|Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986):  434-41|Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989):  147-51|Hoover R, Glass A, Finkle WD, Azevedo D, Milne K "Conjugated estrogens and breast cancer risk in women." J Natl Cancer Inst 67 (1981):  815-20|Thomas DB, Persing JP, Hutchinson WB "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst 69 (1982):  1017-25|Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979):  9-13|Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977):  570-1|Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med 321 (1989):  293-7|Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985):  969-72|Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977):  385-9|Delgado-Rodriguez M, Sillero-Arenas M, Martin-Moreno JM, Galvez-Vargas R "Oral contraceptives and cancer of the cervix uteri. A meta-analysis." Acta Obstet Gynecol Scand 71 (1992):  368-76|Sillero-Arenas M, Rodriguez-Contreras R, Delgado-Rodriguez M, Bueno-Cavanillas A, Galvez-Vargas R "Patterns of research. Oral contraceptives and cervical cancer." Acta Obstet Gynecol Scand 70 (1991):  143-8|Lund E "Oral contraceptives and breast cancer. A review with some comments on mathematical models." Acta Oncol 31 (1992):  183-6|Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S "Breast cancer before age 45 and oral contraceptive use: new findings." Am J Epidemiol 129 (1989):  269-80|Rosenberg L, Palmer JR, Clarke EA, Shapiro S "A case-control study of the risk of breast cancer in relation to oral contraceptive use." Am J Epidemiol 136 (1992):  1437-44|Schlesselman JJ "Oral contraceptives and breast cancer." Am J Obstet Gynecol 163 (1990):  1379-87|Turnquest MA "Oral contraceptive use and incidence of cervical intraepithelial neoplasia." Am J Obstet Gynecol 168 (1993):  1895-6|Kaunitz AM "Oral contraceptives and gynecologic cancer: an update for the 1990s." Am J Obstet Gynecol 167 (1992):  1171-6|Romieu I, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE "Prospective study of oral contraceptive use and risk of breast cancer in women." J Natl Cancer Inst 81 (1989):  1313-21|Olsson H, Moller TR, Ranstam J "Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden." J Natl Cancer Inst 81 (1989):  1000-4|Jones MW, Silverberg SG "Cervical adenocarcinoma in young women: possible relationship to microglandular hyperplasia and use of oral contraceptives." Obstet Gynecol 73 (1989):  984-9|Murray PP, Stadel BV, Schlesselman JJ "Oral contraceptive use in women with a family history of breast cancer." Obstet Gynecol 73 (1989):  977-83|Thomas DB "Oral contraceptives and breast cancer: review of the epidemiologic literature." Contraception 43 (1991):  597-642|Brinton LA "Oral contraceptives and cervical neoplasia." Contraception 43 (1991):  581-95|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994):  1213-23|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|Lavecchia C, Negri E, Franceschi S, Talamini R, Amadori D, Filiberti R, Conti E, Montella M, Veronesi A, Parazzini F, Ferraroni M "Oral contraceptives and breast cancer: a cooperative italian study." Int J Cancer 60 (1995):  163-7|Colditz GA, Hankinson SE, Hunter DJ, et al. "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med 332 (1995):  1589-93|Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA "Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women." JAMA 274 (1995):  137-42|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996):  370-5|Zondervan KT, Carpenter LM, Painter R, Vessey MP "Oral contraceptives and cervical cancer - further findings from the oxford family planning association contraceptive study." Br J Cancer 73 (1996):  1291-7|Calle EE, Heath CW, Miraclemcmahill HL, Coates RJ, Liff JM, Franceschi S, Talamini R, Chantarakul N, Koetsawang S, Rachawat D "Breast cancer and hormonal contraceptives: further results." Contraception 54 (suppl (1996):  s1-106|Rettig BA, Lemon HM "Cancers related to contraceptive use." Br J Cancer 74 (1996):  1509-10|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|Greendale GA, Reboussin BA, Sie A, et al. "Effects of estrogen and estrogen-progestin on mammographic parenchymal density." Ann Intern Med 130 (1999):  262-9|Gapstur SM, Morrow M, Sellers TA "Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women''s health study." JAMA 281 (1999):  2091-7|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50531, 13001, 'Estrone sulfate', 'Breast Neoplasms', 'The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation.  High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.', '3', 'Ewertz M "Oral contraceptives and breast cancer risk in Denmark." Eur J Cancer 28A (1992):  1176-81|Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979):  123|Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol 134 (1991):  1386-95|Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol 134 (1991):  1375-85|Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981):  497-506|Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986):  434-41|Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989):  147-51|Hoover R, Glass A, Finkle WD, Azevedo D, Milne K "Conjugated estrogens and breast cancer risk in women." J Natl Cancer Inst 67 (1981):  815-20|Thomas DB, Persing JP, Hutchinson WB "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst 69 (1982):  1017-25|Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979):  9-13|Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977):  570-1|Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med 321 (1989):  293-7|Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985):  969-72|Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977):  385-9|Delgado-Rodriguez M, Sillero-Arenas M, Martin-Moreno JM, Galvez-Vargas R "Oral contraceptives and cancer of the cervix uteri. A meta-analysis." Acta Obstet Gynecol Scand 71 (1992):  368-76|Sillero-Arenas M, Rodriguez-Contreras R, Delgado-Rodriguez M, Bueno-Cavanillas A, Galvez-Vargas R "Patterns of research. Oral contraceptives and cervical cancer." Acta Obstet Gynecol Scand 70 (1991):  143-8|Lund E "Oral contraceptives and breast cancer. A review with some comments on mathematical models." Acta Oncol 31 (1992):  183-6|Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S "Breast cancer before age 45 and oral contraceptive use: new findings." Am J Epidemiol 129 (1989):  269-80|Rosenberg L, Palmer JR, Clarke EA, Shapiro S "A case-control study of the risk of breast cancer in relation to oral contraceptive use." Am J Epidemiol 136 (1992):  1437-44|Schlesselman JJ "Oral contraceptives and breast cancer." Am J Obstet Gynecol 163 (1990):  1379-87|Turnquest MA "Oral contraceptive use and incidence of cervical intraepithelial neoplasia." Am J Obstet Gynecol 168 (1993):  1895-6|Kaunitz AM "Oral contraceptives and gynecologic cancer: an update for the 1990s." Am J Obstet Gynecol 167 (1992):  1171-6|Romieu I, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE "Prospective study of oral contraceptive use and risk of breast cancer in women." J Natl Cancer Inst 81 (1989):  1313-21|Olsson H, Moller TR, Ranstam J "Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden." J Natl Cancer Inst 81 (1989):  1000-4|Jones MW, Silverberg SG "Cervical adenocarcinoma in young women: possible relationship to microglandular hyperplasia and use of oral contraceptives." Obstet Gynecol 73 (1989):  984-9|Murray PP, Stadel BV, Schlesselman JJ "Oral contraceptive use in women with a family history of breast cancer." Obstet Gynecol 73 (1989):  977-83|Thomas DB "Oral contraceptives and breast cancer: review of the epidemiologic literature." Contraception 43 (1991):  597-642|Brinton LA "Oral contraceptives and cervical neoplasia." Contraception 43 (1991):  581-95|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994):  1213-23|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|Lavecchia C, Negri E, Franceschi S, Talamini R, Amadori D, Filiberti R, Conti E, Montella M, Veronesi A, Parazzini F, Ferraroni M "Oral contraceptives and breast cancer: a cooperative italian study." Int J Cancer 60 (1995):  163-7|Colditz GA, Hankinson SE, Hunter DJ, et al. "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med 332 (1995):  1589-93|Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA "Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women." JAMA 274 (1995):  137-42|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996):  370-5|Zondervan KT, Carpenter LM, Painter R, Vessey MP "Oral contraceptives and cervical cancer - further findings from the oxford family planning association contraceptive study." Br J Cancer 73 (1996):  1291-7|Calle EE, Heath CW, Miraclemcmahill HL, Coates RJ, Liff JM, Franceschi S, Talamini R, Chantarakul N, Koetsawang S, Rachawat D "Breast cancer and hormonal contraceptives: further results." Contraception 54 (suppl (1996):  s1-106|Rettig BA, Lemon HM "Cancers related to contraceptive use." Br J Cancer 74 (1996):  1509-10|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|Greendale GA, Reboussin BA, Sie A, et al. "Effects of estrogen and estrogen-progestin on mammographic parenchymal density." Ann Intern Med 130 (1999):  262-9|Gapstur SM, Morrow M, Sellers TA "Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women''s health study." JAMA 281 (1999):  2091-7|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50532, 13002, 'Estrone sulfate', 'Breast Neoplasms', 'The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation.  High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.', '3', 'Ewertz M "Oral contraceptives and breast cancer risk in Denmark." Eur J Cancer 28A (1992):  1176-81|Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979):  123|Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol 134 (1991):  1386-95|Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol 134 (1991):  1375-85|Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981):  497-506|Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986):  434-41|Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989):  147-51|Hoover R, Glass A, Finkle WD, Azevedo D, Milne K "Conjugated estrogens and breast cancer risk in women." J Natl Cancer Inst 67 (1981):  815-20|Thomas DB, Persing JP, Hutchinson WB "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst 69 (1982):  1017-25|Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979):  9-13|Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977):  570-1|Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med 321 (1989):  293-7|Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985):  969-72|Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977):  385-9|Delgado-Rodriguez M, Sillero-Arenas M, Martin-Moreno JM, Galvez-Vargas R "Oral contraceptives and cancer of the cervix uteri. A meta-analysis." Acta Obstet Gynecol Scand 71 (1992):  368-76|Sillero-Arenas M, Rodriguez-Contreras R, Delgado-Rodriguez M, Bueno-Cavanillas A, Galvez-Vargas R "Patterns of research. Oral contraceptives and cervical cancer." Acta Obstet Gynecol Scand 70 (1991):  143-8|Lund E "Oral contraceptives and breast cancer. A review with some comments on mathematical models." Acta Oncol 31 (1992):  183-6|Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S "Breast cancer before age 45 and oral contraceptive use: new findings." Am J Epidemiol 129 (1989):  269-80|Rosenberg L, Palmer JR, Clarke EA, Shapiro S "A case-control study of the risk of breast cancer in relation to oral contraceptive use." Am J Epidemiol 136 (1992):  1437-44|Schlesselman JJ "Oral contraceptives and breast cancer." Am J Obstet Gynecol 163 (1990):  1379-87|Turnquest MA "Oral contraceptive use and incidence of cervical intraepithelial neoplasia." Am J Obstet Gynecol 168 (1993):  1895-6|Kaunitz AM "Oral contraceptives and gynecologic cancer: an update for the 1990s." Am J Obstet Gynecol 167 (1992):  1171-6|Romieu I, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE "Prospective study of oral contraceptive use and risk of breast cancer in women." J Natl Cancer Inst 81 (1989):  1313-21|Olsson H, Moller TR, Ranstam J "Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden." J Natl Cancer Inst 81 (1989):  1000-4|Jones MW, Silverberg SG "Cervical adenocarcinoma in young women: possible relationship to microglandular hyperplasia and use of oral contraceptives." Obstet Gynecol 73 (1989):  984-9|Murray PP, Stadel BV, Schlesselman JJ "Oral contraceptive use in women with a family history of breast cancer." Obstet Gynecol 73 (1989):  977-83|Thomas DB "Oral contraceptives and breast cancer: review of the epidemiologic literature." Contraception 43 (1991):  597-642|Brinton LA "Oral contraceptives and cervical neoplasia." Contraception 43 (1991):  581-95|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994):  1213-23|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|Lavecchia C, Negri E, Franceschi S, Talamini R, Amadori D, Filiberti R, Conti E, Montella M, Veronesi A, Parazzini F, Ferraroni M "Oral contraceptives and breast cancer: a cooperative italian study." Int J Cancer 60 (1995):  163-7|Colditz GA, Hankinson SE, Hunter DJ, et al. "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med 332 (1995):  1589-93|Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA "Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women." JAMA 274 (1995):  137-42|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996):  370-5|Zondervan KT, Carpenter LM, Painter R, Vessey MP "Oral contraceptives and cervical cancer - further findings from the oxford family planning association contraceptive study." Br J Cancer 73 (1996):  1291-7|Calle EE, Heath CW, Miraclemcmahill HL, Coates RJ, Liff JM, Franceschi S, Talamini R, Chantarakul N, Koetsawang S, Rachawat D "Breast cancer and hormonal contraceptives: further results." Contraception 54 (suppl (1996):  s1-106|Rettig BA, Lemon HM "Cancers related to contraceptive use." Br J Cancer 74 (1996):  1509-10|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|Greendale GA, Reboussin BA, Sie A, et al. "Effects of estrogen and estrogen-progestin on mammographic parenchymal density." Ann Intern Med 130 (1999):  262-9|Gapstur SM, Morrow M, Sellers TA "Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women''s health study." JAMA 281 (1999):  2091-7|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50533, 5485, 'Estrone sulfate', 'Hypertension', 'The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension.  Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.  Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity.  These effects also increase with duration of therapy and patient age.  Therapy with estrogens should be administered cautiously in patients with preexisting hypertension.  Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary.  In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.', '3', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|Williams RS "Benefits and risks of oral contraceptive use." Postgrad Med 92 (1992):  155-7|Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978):  33-55|Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971):  13-21|Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980):  339-42|Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978):  1407-8|Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981):  528-31|Rosenberg L, Palmer JR, Lesko SM, Shapiro S "Oral contraceptive use and the risk of myocardial infarction." Am J Epidemiol 131 (1990):  1009-16|Thorogood M, Mann J, Murphy M, Vessey M "Fatal stroke and use of oral contraceptives: findings from a case- control study." Am J Epidemiol 136 (1992):  35-45|Leaf DA, Bland D, Schaad D, Neighbor WE, Scott CS "Oral contraceptive use and coronary risk factors in women." Am J Med Sci 301 (1991):  365-8|Thorneycroft IH "Oral contraceptives and myocardial infarction." Am J Obstet Gynecol 163 (1990):  1393-7|Lidegaard O "Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study." BMJ 306 (1993):  956-63|Derman RJ "Oral contraceptives and cardiovascular risk. Taking a safe course of action." Postgrad Med 88 (1990):  119-22|Hannaford PC, Croft PR, Kay CR "Oral contraception and stroke. Evidence from the Royal College of General Practitioners'' Oral Contraception Study." Stroke 25 (1994):  935-42|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Peterson HB, Lee NC "Long-term health risks and benefits of oral contraceptive use." Obstet Gynecol Clin North Am 17 (1990):  775-88|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses'' Health Study." N Engl J Med 325 (1991):  756-62|Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991):  1861-7|Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989):  1095-2100|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995):  1-16|The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995):  199-208|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|Norris LA, Bonnar J "The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives." Br J Obstet Gynaecol 103 (1996):  261-7|Levine AB, Teppa J, Mcgough B, Cowchock FS "Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives." Contraception 53 (1996):  255-7|Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK "Stroke in users of low-dose oral contraceptives." N Engl J Med 335 (1996):  8-15|Speroff L "Oral contraceptives and venous thromboembolism." Int J Gynaecol Obstet 54 (1996):  45-50|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG, Debertribeiro M, Medina E, Artigas J, Shen H, Zhong YH, Zhang DW, "Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  498-505|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG "Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  505-10|Piegsa K, Guillebaud J "Oral contraceptives and the risk of DVT." Practitioner 240 (1996):  544|Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM "Oral contraceptives are a risk factor for cerebral vein thrombosis." Thromb Haemost 76 (1996):  477-8|Farley TMM, Meirik O, Poulter NR, Chang CL, Marmot MG "Oral contraceptives and thrombotic diseases: impact of new epidemiological studies." Contraception 54 (1996):  193-5|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|Sidney S, Petitti DB, Quesenberry CP "Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women." Ann Intern Med 127 (1997):  501-8|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|Thorogood M "Risk of stroke in users of oral contraceptives." JAMA 281 (1999):  1255-6|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50534, 13001, 'Estrone sulfate', 'Hypertension', 'The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension.  Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.  Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity.  These effects also increase with duration of therapy and patient age.  Therapy with estrogens should be administered cautiously in patients with preexisting hypertension.  Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary.  In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.', '3', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|Williams RS "Benefits and risks of oral contraceptive use." Postgrad Med 92 (1992):  155-7|Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978):  33-55|Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971):  13-21|Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980):  339-42|Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978):  1407-8|Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981):  528-31|Rosenberg L, Palmer JR, Lesko SM, Shapiro S "Oral contraceptive use and the risk of myocardial infarction." Am J Epidemiol 131 (1990):  1009-16|Thorogood M, Mann J, Murphy M, Vessey M "Fatal stroke and use of oral contraceptives: findings from a case- control study." Am J Epidemiol 136 (1992):  35-45|Leaf DA, Bland D, Schaad D, Neighbor WE, Scott CS "Oral contraceptive use and coronary risk factors in women." Am J Med Sci 301 (1991):  365-8|Thorneycroft IH "Oral contraceptives and myocardial infarction." Am J Obstet Gynecol 163 (1990):  1393-7|Lidegaard O "Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study." BMJ 306 (1993):  956-63|Derman RJ "Oral contraceptives and cardiovascular risk. Taking a safe course of action." Postgrad Med 88 (1990):  119-22|Hannaford PC, Croft PR, Kay CR "Oral contraception and stroke. Evidence from the Royal College of General Practitioners'' Oral Contraception Study." Stroke 25 (1994):  935-42|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Peterson HB, Lee NC "Long-term health risks and benefits of oral contraceptive use." Obstet Gynecol Clin North Am 17 (1990):  775-88|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses'' Health Study." N Engl J Med 325 (1991):  756-62|Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991):  1861-7|Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989):  1095-2100|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995):  1-16|The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995):  199-208|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|Norris LA, Bonnar J "The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives." Br J Obstet Gynaecol 103 (1996):  261-7|Levine AB, Teppa J, Mcgough B, Cowchock FS "Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives." Contraception 53 (1996):  255-7|Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK "Stroke in users of low-dose oral contraceptives." N Engl J Med 335 (1996):  8-15|Speroff L "Oral contraceptives and venous thromboembolism." Int J Gynaecol Obstet 54 (1996):  45-50|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG, Debertribeiro M, Medina E, Artigas J, Shen H, Zhong YH, Zhang DW, "Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  498-505|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG "Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  505-10|Piegsa K, Guillebaud J "Oral contraceptives and the risk of DVT." Practitioner 240 (1996):  544|Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM "Oral contraceptives are a risk factor for cerebral vein thrombosis." Thromb Haemost 76 (1996):  477-8|Farley TMM, Meirik O, Poulter NR, Chang CL, Marmot MG "Oral contraceptives and thrombotic diseases: impact of new epidemiological studies." Contraception 54 (1996):  193-5|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|Sidney S, Petitti DB, Quesenberry CP "Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women." Ann Intern Med 127 (1997):  501-8|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|Thorogood M "Risk of stroke in users of oral contraceptives." JAMA 281 (1999):  1255-6|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50535, 13002, 'Estrone sulfate', 'Hypertension', 'The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension.  Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.  Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity.  These effects also increase with duration of therapy and patient age.  Therapy with estrogens should be administered cautiously in patients with preexisting hypertension.  Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary.  In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.', '3', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|Williams RS "Benefits and risks of oral contraceptive use." Postgrad Med 92 (1992):  155-7|Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978):  33-55|Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971):  13-21|Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980):  339-42|Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978):  1407-8|Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981):  528-31|Rosenberg L, Palmer JR, Lesko SM, Shapiro S "Oral contraceptive use and the risk of myocardial infarction." Am J Epidemiol 131 (1990):  1009-16|Thorogood M, Mann J, Murphy M, Vessey M "Fatal stroke and use of oral contraceptives: findings from a case- control study." Am J Epidemiol 136 (1992):  35-45|Leaf DA, Bland D, Schaad D, Neighbor WE, Scott CS "Oral contraceptive use and coronary risk factors in women." Am J Med Sci 301 (1991):  365-8|Thorneycroft IH "Oral contraceptives and myocardial infarction." Am J Obstet Gynecol 163 (1990):  1393-7|Lidegaard O "Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study." BMJ 306 (1993):  956-63|Derman RJ "Oral contraceptives and cardiovascular risk. Taking a safe course of action." Postgrad Med 88 (1990):  119-22|Hannaford PC, Croft PR, Kay CR "Oral contraception and stroke. Evidence from the Royal College of General Practitioners'' Oral Contraception Study." Stroke 25 (1994):  935-42|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Peterson HB, Lee NC "Long-term health risks and benefits of oral contraceptive use." Obstet Gynecol Clin North Am 17 (1990):  775-88|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses'' Health Study." N Engl J Med 325 (1991):  756-62|Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991):  1861-7|Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989):  1095-2100|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995):  1-16|The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995):  199-208|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|Norris LA, Bonnar J "The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives." Br J Obstet Gynaecol 103 (1996):  261-7|Levine AB, Teppa J, Mcgough B, Cowchock FS "Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives." Contraception 53 (1996):  255-7|Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK "Stroke in users of low-dose oral contraceptives." N Engl J Med 335 (1996):  8-15|Speroff L "Oral contraceptives and venous thromboembolism." Int J Gynaecol Obstet 54 (1996):  45-50|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG, Debertribeiro M, Medina E, Artigas J, Shen H, Zhong YH, Zhang DW, "Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  498-505|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG "Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  505-10|Piegsa K, Guillebaud J "Oral contraceptives and the risk of DVT." Practitioner 240 (1996):  544|Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM "Oral contraceptives are a risk factor for cerebral vein thrombosis." Thromb Haemost 76 (1996):  477-8|Farley TMM, Meirik O, Poulter NR, Chang CL, Marmot MG "Oral contraceptives and thrombotic diseases: impact of new epidemiological studies." Contraception 54 (1996):  193-5|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|Sidney S, Petitti DB, Quesenberry CP "Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women." Ann Intern Med 127 (1997):  501-8|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|Thorogood M "Risk of stroke in users of oral contraceptives." JAMA 281 (1999):  1255-6|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50536, 5485, 'Estrone sulfate', 'Thromboembolism', 'The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic or thromboembolic disorders.  The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease.  Females with a history of migraines with aura are at an increased risk for stroke and this stroke risk may be further increased in females who have migraines with aura with use of combination oral contraceptives.  Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy.  Although the clinical significance of these effects is unknown, epidemiological data suggest it may be dose-dependent.  The risk is probably slight with the use of newer, low-dose oral contraceptives in the absence of known risk factors (e.g., smoker, particularly over the age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40).  However, a much more significant risk has been reported with higher dosages, such as those used to treat prostate or metastatic breast cancer or those used in older formulations of birth control pills.  Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits.  Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.', '3', 'Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985):  73-83|Meade TW "Oral contraceptives, clotting factors, and thrombosis." Am J Obstet Gynecol 142 (1982):  758-61|Williams RS "Benefits and risks of oral contraceptive use." Postgrad Med 92 (1992):  155-7|Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980):  339-42|Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978):  1407-8|Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Della Volpe A, Zanussi C "Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women." Thromb Res 62 (1991):  1-8|Rosenberg L, Palmer JR, Lesko SM, Shapiro S "Oral contraceptive use and the risk of myocardial infarction." Am J Epidemiol 131 (1990):  1009-16|Thorogood M, Mann J, Murphy M, Vessey M "Fatal stroke and use of oral contraceptives: findings from a case- control study." Am J Epidemiol 136 (1992):  35-45|Leaf DA, Bland D, Schaad D, Neighbor WE, Scott CS "Oral contraceptive use and coronary risk factors in women." Am J Med Sci 301 (1991):  365-8|Thorneycroft IH "Oral contraceptives and myocardial infarction." Am J Obstet Gynecol 163 (1990):  1393-7|Lidegaard O "Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study." BMJ 306 (1993):  956-63|Derman RJ "Oral contraceptives and cardiovascular risk. Taking a safe course of action." Postgrad Med 88 (1990):  119-22|Hannaford PC, Croft PR, Kay CR "Oral contraception and stroke. Evidence from the Royal College of General Practitioners'' Oral Contraception Study." Stroke 25 (1994):  935-42|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Miwa LJ, Edmunds AL, Shaefer MS, Raynor SC "Idiopathic thromboembolism associated with triphasic oral contraceptives." DICP 23 (1989):  773-5|Beaumont V, Lemort N, Beaumont JL "Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases." Eur Heart J 12 (1991):  1219-24|Key JD, Hammill WW, Everett L "Pulmonary embolus in an adolescent on oral contraceptives." J Adolesc Health 13 (1992):  713-5|Burkman RT Jr "Benefits and risk of oral contraceptives. A reassessment." J Reprod Med 36 (1991):  217-8|Peterson HB, Lee NC "Long-term health risks and benefits of oral contraceptive use." Obstet Gynecol Clin North Am 17 (1990):  775-88|Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974):  15-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|Devor M, Barrett-Connor E, Renvall M, Feigal D, Ramsdell J "Estrogen replacement therapy and the risk of venous thrombosis." Am J Med 92 (1992):  275-81|Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991):  1861-7|Grady D, Rubin SM, Petiti DB, et al. "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med 117 (1992):  1016-36|Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989):  1095-2100|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995):  1-16|Lidegaard O "Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease." Br J Obstet Gynaecol 102 (1995):  153-9|The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995):  199-208|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|Norris LA, Bonnar J "The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives." Br J Obstet Gynaecol 103 (1996):  261-7|Levine AB, Teppa J, Mcgough B, Cowchock FS "Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives." Contraception 53 (1996):  255-7|Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK "Stroke in users of low-dose oral contraceptives." N Engl J Med 335 (1996):  8-15|Speroff L "Oral contraceptives and venous thromboembolism." Int J Gynaecol Obstet 54 (1996):  45-50|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG, Debertribeiro M, Medina E, Artigas J, Shen H, Zhong YH, Zhang DW, "Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  498-505|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG "Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  505-10|Piegsa K, Guillebaud J "Oral contraceptives and the risk of DVT." Practitioner 240 (1996):  544|Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM "Oral contraceptives are a risk factor for cerebral vein thrombosis." Thromb Haemost 76 (1996):  477-8|Farley TMM, Meirik O, Poulter NR, Chang CL, Marmot MG "Oral contraceptives and thrombotic diseases: impact of new epidemiological studies." Contraception 54 (1996):  193-5|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|Sidney S, Petitti DB, Quesenberry CP "Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women." Ann Intern Med 127 (1997):  501-8|Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998):  605-13|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|Petitti DB "Hormone replacement therapy and heart disease prevention: experimentation trumps observation." JAMA 280 (1998):  650-2|Thorogood M "Risk of stroke in users of oral contraceptives." JAMA 281 (1999):  1255-6|Mendelsohn ME, Karas RH "The protective effects of estrogen on the cardiovascular system." N Engl J Med 340 (1999):  1801-11|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50537, 13001, 'Estrone sulfate', 'Thromboembolism', 'The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic or thromboembolic disorders.  The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease.  Females with a history of migraines with aura are at an increased risk for stroke and this stroke risk may be further increased in females who have migraines with aura with use of combination oral contraceptives.  Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy.  Although the clinical significance of these effects is unknown, epidemiological data suggest it may be dose-dependent.  The risk is probably slight with the use of newer, low-dose oral contraceptives in the absence of known risk factors (e.g., smoker, particularly over the age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40).  However, a much more significant risk has been reported with higher dosages, such as those used to treat prostate or metastatic breast cancer or those used in older formulations of birth control pills.  Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits.  Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.', '3', 'Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985):  73-83|Meade TW "Oral contraceptives, clotting factors, and thrombosis." Am J Obstet Gynecol 142 (1982):  758-61|Williams RS "Benefits and risks of oral contraceptive use." Postgrad Med 92 (1992):  155-7|Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980):  339-42|Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978):  1407-8|Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Della Volpe A, Zanussi C "Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women." Thromb Res 62 (1991):  1-8|Rosenberg L, Palmer JR, Lesko SM, Shapiro S "Oral contraceptive use and the risk of myocardial infarction." Am J Epidemiol 131 (1990):  1009-16|Thorogood M, Mann J, Murphy M, Vessey M "Fatal stroke and use of oral contraceptives: findings from a case- control study." Am J Epidemiol 136 (1992):  35-45|Leaf DA, Bland D, Schaad D, Neighbor WE, Scott CS "Oral contraceptive use and coronary risk factors in women." Am J Med Sci 301 (1991):  365-8|Thorneycroft IH "Oral contraceptives and myocardial infarction." Am J Obstet Gynecol 163 (1990):  1393-7|Lidegaard O "Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study." BMJ 306 (1993):  956-63|Derman RJ "Oral contraceptives and cardiovascular risk. Taking a safe course of action." Postgrad Med 88 (1990):  119-22|Hannaford PC, Croft PR, Kay CR "Oral contraception and stroke. Evidence from the Royal College of General Practitioners'' Oral Contraception Study." Stroke 25 (1994):  935-42|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Miwa LJ, Edmunds AL, Shaefer MS, Raynor SC "Idiopathic thromboembolism associated with triphasic oral contraceptives." DICP 23 (1989):  773-5|Beaumont V, Lemort N, Beaumont JL "Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases." Eur Heart J 12 (1991):  1219-24|Key JD, Hammill WW, Everett L "Pulmonary embolus in an adolescent on oral contraceptives." J Adolesc Health 13 (1992):  713-5|Burkman RT Jr "Benefits and risk of oral contraceptives. A reassessment." J Reprod Med 36 (1991):  217-8|Peterson HB, Lee NC "Long-term health risks and benefits of oral contraceptive use." Obstet Gynecol Clin North Am 17 (1990):  775-88|Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974):  15-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|Devor M, Barrett-Connor E, Renvall M, Feigal D, Ramsdell J "Estrogen replacement therapy and the risk of venous thrombosis." Am J Med 92 (1992):  275-81|Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991):  1861-7|Grady D, Rubin SM, Petiti DB, et al. "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med 117 (1992):  1016-36|Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989):  1095-2100|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995):  1-16|Lidegaard O "Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease." Br J Obstet Gynaecol 102 (1995):  153-9|The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995):  199-208|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|Norris LA, Bonnar J "The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives." Br J Obstet Gynaecol 103 (1996):  261-7|Levine AB, Teppa J, Mcgough B, Cowchock FS "Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives." Contraception 53 (1996):  255-7|Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK "Stroke in users of low-dose oral contraceptives." N Engl J Med 335 (1996):  8-15|Speroff L "Oral contraceptives and venous thromboembolism." Int J Gynaecol Obstet 54 (1996):  45-50|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG, Debertribeiro M, Medina E, Artigas J, Shen H, Zhong YH, Zhang DW, "Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  498-505|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG "Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  505-10|Piegsa K, Guillebaud J "Oral contraceptives and the risk of DVT." Practitioner 240 (1996):  544|Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM "Oral contraceptives are a risk factor for cerebral vein thrombosis." Thromb Haemost 76 (1996):  477-8|Farley TMM, Meirik O, Poulter NR, Chang CL, Marmot MG "Oral contraceptives and thrombotic diseases: impact of new epidemiological studies." Contraception 54 (1996):  193-5|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|Sidney S, Petitti DB, Quesenberry CP "Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women." Ann Intern Med 127 (1997):  501-8|Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998):  605-13|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|Petitti DB "Hormone replacement therapy and heart disease prevention: experimentation trumps observation." JAMA 280 (1998):  650-2|Thorogood M "Risk of stroke in users of oral contraceptives." JAMA 281 (1999):  1255-6|Mendelsohn ME, Karas RH "The protective effects of estrogen on the cardiovascular system." N Engl J Med 340 (1999):  1801-11|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50538, 13002, 'Estrone sulfate', 'Thromboembolism', 'The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic or thromboembolic disorders.  The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease.  Females with a history of migraines with aura are at an increased risk for stroke and this stroke risk may be further increased in females who have migraines with aura with use of combination oral contraceptives.  Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy.  Although the clinical significance of these effects is unknown, epidemiological data suggest it may be dose-dependent.  The risk is probably slight with the use of newer, low-dose oral contraceptives in the absence of known risk factors (e.g., smoker, particularly over the age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40).  However, a much more significant risk has been reported with higher dosages, such as those used to treat prostate or metastatic breast cancer or those used in older formulations of birth control pills.  Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits.  Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.', '3', 'Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985):  73-83|Meade TW "Oral contraceptives, clotting factors, and thrombosis." Am J Obstet Gynecol 142 (1982):  758-61|Williams RS "Benefits and risks of oral contraceptive use." Postgrad Med 92 (1992):  155-7|Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980):  339-42|Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978):  1407-8|Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Della Volpe A, Zanussi C "Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women." Thromb Res 62 (1991):  1-8|Rosenberg L, Palmer JR, Lesko SM, Shapiro S "Oral contraceptive use and the risk of myocardial infarction." Am J Epidemiol 131 (1990):  1009-16|Thorogood M, Mann J, Murphy M, Vessey M "Fatal stroke and use of oral contraceptives: findings from a case- control study." Am J Epidemiol 136 (1992):  35-45|Leaf DA, Bland D, Schaad D, Neighbor WE, Scott CS "Oral contraceptive use and coronary risk factors in women." Am J Med Sci 301 (1991):  365-8|Thorneycroft IH "Oral contraceptives and myocardial infarction." Am J Obstet Gynecol 163 (1990):  1393-7|Lidegaard O "Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study." BMJ 306 (1993):  956-63|Derman RJ "Oral contraceptives and cardiovascular risk. Taking a safe course of action." Postgrad Med 88 (1990):  119-22|Hannaford PC, Croft PR, Kay CR "Oral contraception and stroke. Evidence from the Royal College of General Practitioners'' Oral Contraception Study." Stroke 25 (1994):  935-42|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Miwa LJ, Edmunds AL, Shaefer MS, Raynor SC "Idiopathic thromboembolism associated with triphasic oral contraceptives." DICP 23 (1989):  773-5|Beaumont V, Lemort N, Beaumont JL "Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases." Eur Heart J 12 (1991):  1219-24|Key JD, Hammill WW, Everett L "Pulmonary embolus in an adolescent on oral contraceptives." J Adolesc Health 13 (1992):  713-5|Burkman RT Jr "Benefits and risk of oral contraceptives. A reassessment." J Reprod Med 36 (1991):  217-8|Peterson HB, Lee NC "Long-term health risks and benefits of oral contraceptive use." Obstet Gynecol Clin North Am 17 (1990):  775-88|Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974):  15-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|Devor M, Barrett-Connor E, Renvall M, Feigal D, Ramsdell J "Estrogen replacement therapy and the risk of venous thrombosis." Am J Med 92 (1992):  275-81|Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991):  1861-7|Grady D, Rubin SM, Petiti DB, et al. "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med 117 (1992):  1016-36|Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989):  1095-2100|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995):  1-16|Lidegaard O "Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease." Br J Obstet Gynaecol 102 (1995):  153-9|The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995):  199-208|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|Norris LA, Bonnar J "The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives." Br J Obstet Gynaecol 103 (1996):  261-7|Levine AB, Teppa J, Mcgough B, Cowchock FS "Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives." Contraception 53 (1996):  255-7|Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK "Stroke in users of low-dose oral contraceptives." N Engl J Med 335 (1996):  8-15|Speroff L "Oral contraceptives and venous thromboembolism." Int J Gynaecol Obstet 54 (1996):  45-50|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG, Debertribeiro M, Medina E, Artigas J, Shen H, Zhong YH, Zhang DW, "Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  498-505|Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG "Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996):  505-10|Piegsa K, Guillebaud J "Oral contraceptives and the risk of DVT." Practitioner 240 (1996):  544|Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM "Oral contraceptives are a risk factor for cerebral vein thrombosis." Thromb Haemost 76 (1996):  477-8|Farley TMM, Meirik O, Poulter NR, Chang CL, Marmot MG "Oral contraceptives and thrombotic diseases: impact of new epidemiological studies." Contraception 54 (1996):  193-5|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|Sidney S, Petitti DB, Quesenberry CP "Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women." Ann Intern Med 127 (1997):  501-8|Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998):  605-13|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|Petitti DB "Hormone replacement therapy and heart disease prevention: experimentation trumps observation." JAMA 280 (1998):  650-2|Thorogood M "Risk of stroke in users of oral contraceptives." JAMA 281 (1999):  1255-6|Mendelsohn ME, Karas RH "The protective effects of estrogen on the cardiovascular system." N Engl J Med 340 (1999):  1801-11|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50539, 5485, 'Estrone sulfate', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'Tao LC "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer 68 (1991):  341-7|"Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991):  182-5|Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988):  115-9|Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977):  357-9|Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989):  878-82|Mooney MJ, Nyreen MR, Hall RA, Carter PL "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg 59 (1993):  229-31|Gyorffy EJ, Bredfeldt JE, Black WC "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med 110 (1989):  489-90|Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993):  635-7|Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology 97 (1989):  154-7|Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol 16 (1992):  982-7|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50540, 13001, 'Estrone sulfate', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'Tao LC "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer 68 (1991):  341-7|"Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991):  182-5|Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988):  115-9|Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977):  357-9|Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989):  878-82|Mooney MJ, Nyreen MR, Hall RA, Carter PL "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg 59 (1993):  229-31|Gyorffy EJ, Bredfeldt JE, Black WC "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med 110 (1989):  489-90|Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993):  635-7|Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology 97 (1989):  154-7|Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol 16 (1992):  982-7|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50541, 13002, 'Estrone sulfate', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'Tao LC "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer 68 (1991):  341-7|"Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991):  182-5|Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988):  115-9|Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977):  357-9|Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989):  878-82|Mooney MJ, Nyreen MR, Hall RA, Carter PL "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg 59 (1993):  229-31|Gyorffy EJ, Bredfeldt JE, Black WC "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med 110 (1989):  489-90|Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993):  635-7|Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology 97 (1989):  154-7|Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol 16 (1992):  982-7|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50542, 5485, 'Estrone sulfate', 'Angioedema', 'The use of exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema.  Close monitoring is recommended when prescribing these agents to patients predisposed to angioedema.', '2', '"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50543, 13001, 'Estrone sulfate', 'Angioedema', 'The use of exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema.  Close monitoring is recommended when prescribing these agents to patients predisposed to angioedema.', '2', '"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50544, 13002, 'Estrone sulfate', 'Angioedema', 'The use of exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema.  Close monitoring is recommended when prescribing these agents to patients predisposed to angioedema.', '2', '"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50545, 5485, 'Estrone sulfate', 'Gallbladder Diseases', 'A two- to four-fold increase in risk of gallbladder disease has been noted in women receiving postmenopausal estrogen therapy.  The risk for gallbladder disease may be less for premenopausal women using oral contraceptives containing low-dose estrogens and/or progestins.  Therapy with estrogens should be administered cautiously in patients with preexisting gallbladder disease.', '2', 'Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974):  15-9|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50546, 13001, 'Estrone sulfate', 'Gallbladder Diseases', 'A two- to four-fold increase in risk of gallbladder disease has been noted in women receiving postmenopausal estrogen therapy.  The risk for gallbladder disease may be less for premenopausal women using oral contraceptives containing low-dose estrogens and/or progestins.  Therapy with estrogens should be administered cautiously in patients with preexisting gallbladder disease.', '2', 'Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974):  15-9|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50547, 13002, 'Estrone sulfate', 'Gallbladder Diseases', 'A two- to four-fold increase in risk of gallbladder disease has been noted in women receiving postmenopausal estrogen therapy.  The risk for gallbladder disease may be less for premenopausal women using oral contraceptives containing low-dose estrogens and/or progestins.  Therapy with estrogens should be administered cautiously in patients with preexisting gallbladder disease.', '2', 'Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974):  15-9|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50548, 5485, 'Estrone sulfate', 'Hypercalcemia', 'Estrogens influence the metabolism of calcium and phosphorus.  Intestinal absorption and retention of calcium are increased, which may occasionally result in hypercalcemia.  Therapy with estrogens should be administered cautiously in patients with preexisting hypercalcemia, renal dysfunction, or metabolic bone diseases that are associated with hypercalcemia.', '2', '"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Duavee (bazedoxifene-conjugated estrogens)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50549, 13001, 'Estrone sulfate', 'Hypercalcemia', 'Estrogens influence the metabolism of calcium and phosphorus.  Intestinal absorption and retention of calcium are increased, which may occasionally result in hypercalcemia.  Therapy with estrogens should be administered cautiously in patients with preexisting hypercalcemia, renal dysfunction, or metabolic bone diseases that are associated with hypercalcemia.', '2', '"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Duavee (bazedoxifene-conjugated estrogens)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50550, 13002, 'Estrone sulfate', 'Hypercalcemia', 'Estrogens influence the metabolism of calcium and phosphorus.  Intestinal absorption and retention of calcium are increased, which may occasionally result in hypercalcemia.  Therapy with estrogens should be administered cautiously in patients with preexisting hypercalcemia, renal dysfunction, or metabolic bone diseases that are associated with hypercalcemia.', '2', '"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Duavee (bazedoxifene-conjugated estrogens)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50551, 5485, 'Estrone sulfate', 'Hyperlipidemias', 'Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Molitch ME, Oill P, Odell WD "Massive hyperlipemia during estrogen therapy." JAMA 227 (1974):  522-5|Janaud A, Rouffy J, Upmalis D, Dain MP "A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel." Acta Obstet Gynecol Scand Suppl 156 (1992):  33-8|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Burkman RT, Zacur HA, Kimball AW, Kwiterovich P, Bell WR "Oral contraceptives and lipids and lipoproteins: Part I--Variations in mean levels by oral contraceptive type." Contraception 40 (1989):  553-61|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Godsland IF, Crook D "Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk." Am J Obstet Gynecol 170 (1994):  1528-36|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998):  605-13|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50552, 13001, 'Estrone sulfate', 'Hyperlipidemias', 'Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Molitch ME, Oill P, Odell WD "Massive hyperlipemia during estrogen therapy." JAMA 227 (1974):  522-5|Janaud A, Rouffy J, Upmalis D, Dain MP "A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel." Acta Obstet Gynecol Scand Suppl 156 (1992):  33-8|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Burkman RT, Zacur HA, Kimball AW, Kwiterovich P, Bell WR "Oral contraceptives and lipids and lipoproteins: Part I--Variations in mean levels by oral contraceptive type." Contraception 40 (1989):  553-61|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Godsland IF, Crook D "Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk." Am J Obstet Gynecol 170 (1994):  1528-36|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998):  605-13|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50553, 13002, 'Estrone sulfate', 'Hyperlipidemias', 'Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Molitch ME, Oill P, Odell WD "Massive hyperlipemia during estrogen therapy." JAMA 227 (1974):  522-5|Janaud A, Rouffy J, Upmalis D, Dain MP "A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel." Acta Obstet Gynecol Scand Suppl 156 (1992):  33-8|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Burkman RT, Zacur HA, Kimball AW, Kwiterovich P, Bell WR "Oral contraceptives and lipids and lipoproteins: Part I--Variations in mean levels by oral contraceptive type." Contraception 40 (1989):  553-61|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Godsland IF, Crook D "Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk." Am J Obstet Gynecol 170 (1994):  1528-36|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998):  605-13|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50554, 5485, 'Estrone sulfate', 'Liver Diseases', 'Estrogens are primarily metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for adverse effects associated with estrogen administration due to decreased drug clearance.  Therapy with estrogens should be administered cautiously in patients with liver disease.  In addition, clinicians should be aware that estrogen therapy may affect liver function tests.  Increased sulfobromophthalein retention has been reported with the use of estrogen-containing oral contraceptives and may be expected with larger doses of estrogens.', '2', 'Bhavnani BR, Cecutti A "Pharmacokinetics of 17 beta-dihydroequilin sulfate and 17 beta- dihydroequilin in normal postmenopausal women." J Clin Endocrinol Metab 78 (1994):  197-204|Adlercrueuta H "Hepatic metabolism of estrogens in health and disease." N Engl J Med 290 (1974):  1081-3|Goldzieher JW "Pharmacology of contraceptive steroids: a brief review." Am J Obstet Gynecol 160 (1989):  1260-4|Kuhnz W, al-Yacoub G, Fuhrmeister A "Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and the same contraceptive formulation." Contraception 46 (1992):  455-69|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50555, 13001, 'Estrone sulfate', 'Liver Diseases', 'Estrogens are primarily metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for adverse effects associated with estrogen administration due to decreased drug clearance.  Therapy with estrogens should be administered cautiously in patients with liver disease.  In addition, clinicians should be aware that estrogen therapy may affect liver function tests.  Increased sulfobromophthalein retention has been reported with the use of estrogen-containing oral contraceptives and may be expected with larger doses of estrogens.', '2', 'Bhavnani BR, Cecutti A "Pharmacokinetics of 17 beta-dihydroequilin sulfate and 17 beta- dihydroequilin in normal postmenopausal women." J Clin Endocrinol Metab 78 (1994):  197-204|Adlercrueuta H "Hepatic metabolism of estrogens in health and disease." N Engl J Med 290 (1974):  1081-3|Goldzieher JW "Pharmacology of contraceptive steroids: a brief review." Am J Obstet Gynecol 160 (1989):  1260-4|Kuhnz W, al-Yacoub G, Fuhrmeister A "Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and the same contraceptive formulation." Contraception 46 (1992):  455-69|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50556, 13002, 'Estrone sulfate', 'Liver Diseases', 'Estrogens are primarily metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for adverse effects associated with estrogen administration due to decreased drug clearance.  Therapy with estrogens should be administered cautiously in patients with liver disease.  In addition, clinicians should be aware that estrogen therapy may affect liver function tests.  Increased sulfobromophthalein retention has been reported with the use of estrogen-containing oral contraceptives and may be expected with larger doses of estrogens.', '2', 'Bhavnani BR, Cecutti A "Pharmacokinetics of 17 beta-dihydroequilin sulfate and 17 beta- dihydroequilin in normal postmenopausal women." J Clin Endocrinol Metab 78 (1994):  197-204|Adlercrueuta H "Hepatic metabolism of estrogens in health and disease." N Engl J Med 290 (1974):  1081-3|Goldzieher JW "Pharmacology of contraceptive steroids: a brief review." Am J Obstet Gynecol 160 (1989):  1260-4|Kuhnz W, al-Yacoub G, Fuhrmeister A "Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and the same contraceptive formulation." Contraception 46 (1992):  455-69|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50557, 5485, 'Estrone sulfate', 'Melanosis', 'The use of exogenous estrogens may occasionally cause chloasma, especially in women with a history of chloasma gravidarum.  Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking combination oral contraceptives.', '2', '"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50558, 13001, 'Estrone sulfate', 'Melanosis', 'The use of exogenous estrogens may occasionally cause chloasma, especially in women with a history of chloasma gravidarum.  Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking combination oral contraceptives.', '2', '"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50559, 13002, 'Estrone sulfate', 'Melanosis', 'The use of exogenous estrogens may occasionally cause chloasma, especially in women with a history of chloasma gravidarum.  Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking combination oral contraceptives.', '2', '"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50560, 5485, 'Estrone sulfate', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50561, 13001, 'Estrone sulfate', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50562, 13002, 'Estrone sulfate', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50563, 5485, 'Estrone sulfate', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50564, 13001, 'Estrone sulfate', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50565, 13002, 'Estrone sulfate', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50566, 5485, 'Estrone sulfate', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50567, 13001, 'Estrone sulfate', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50568, 13002, 'Estrone sulfate', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50569, 5485, 'Estrone sulfate', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50570, 13001, 'Estrone sulfate', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50571, 13002, 'Estrone sulfate', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50572, 5485, 'Estrone sulfate', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50573, 13001, 'Estrone sulfate', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50574, 13002, 'Estrone sulfate', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50575, 4829, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50576, 4832, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50577, 4833, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50578, 5268, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50579, 8937, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50580, 10561, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50581, 10562, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50582, 22202, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50583, 23437, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50584, 23589, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50585, 23590, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50586, 27085, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50587, 27088, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50588, 31620, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50589, 4829, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50590, 4832, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50591, 4833, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50592, 5268, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50593, 8937, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50594, 10561, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50595, 10562, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50596, 22202, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50597, 23437, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50598, 23589, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50599, 23590, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50600, 27085, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50601, 27088, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50602, 31620, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50603, 4829, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50604, 4832, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50605, 4833, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50606, 5268, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50607, 8937, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50608, 10561, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50609, 10562, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50610, 22202, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50611, 23437, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50612, 23589, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50613, 23590, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50614, 27085, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50615, 27088, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50616, 31620, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50617, 24890, 'Etacrynic acid', 'Anuria', 'The use of loop diuretics is contraindicated in patients with anuria.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50618, 24890, 'Etacrynic acid', 'Fibrosis', 'Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites.  Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia.  Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis.  Loop diuretics should be withheld in patients with hepatic coma until the condition improves.', '3', 'Ring-Larsen H "Bumetanide in the treatment of hepatic ascites. A short and long-term study." Acta Med Scand 195 (1974):  411-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Lieberman FL, Reynolds TB "The use of ethacrynic acid in patients with cirrhosis and ascites." Gastroenterology 49 (1965):  531-8|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Knauf H, Mutschler E "Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide." Cardiology 84 (1994):  87-98', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50619, 24890, 'Etacrynic acid', 'Water-Electrolyte Imbalance', 'The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow.  Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction.  Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.  Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.', '3', 'Tambyah JA, Lim MK "Effect of furesomide on calcium excretion." Br Med J 03/22/69 (1969):  751-2|Roesner M "The loop diuretics: focus on furosemide and ethacrynic acid." N C Med J 47 (1986):  93-6|Ponto LL, Schoenwald RD "Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review." Clin Pharmacokinet 18 (1990):  381-408|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Kubik MM, Bowers E, Underwood PN "Longterm experience of the routine use of bumetanide." Br J Clin Pract 30 (1976):  11-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz AB "Diuretic-induced hypokalemia." Am Fam Physician 11 (1975):  101-4|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|DeRubertis FR, Michelis MF, Beck N, Davis BB "Complications of diuretic therapy: severe alkalosis and syndrome resembling inappropriate secretion of antidiuretic hormone." Metabolism 19 (1970):  709-19|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|Schmidt P, Friedman IS "Adverse effects of ethacrynic acid." N Y State J Med 67 (1967):  1438-42|Martinez-Maldonado M "Electrolyte disturbances resulting from diuretic therapy." Tex Med 69 (1973):  83-7|Gaillard R, Vallotton B, Muller F "Letter: Hypotension after angiotensin-II infusion and hypovolaemia induced by diuretic." Lancet 1 (1974):  1349|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Patterson JH, Adams KF, Applefeld MM, Corder CN, Masse BR "Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion." Pharmacotherapy 14 (1994):  514-21|Oberbauer R, Krivanek P, Turnheim K "Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly." Clin Pharmacol Ther 57 (1995):  42-51|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50620, 24890, 'Etacrynic acid', 'Ototoxicity', 'Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics.  Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents.  Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  High-dose parenteral therapy should be administered as controlled infusion.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Vargish T, Benjamin R, Shenkman L "Deafness from furosemide." Ann Intern Med 72 (1970):  761|Quick CA, Hoppe W "Permanent deafness associated with furosemide administration." Ann Otol Rhinol Laryngol 84 (1975):  94-101|David D, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328|Heidland A, Wigand N "Influence of high doses of furosemide on hearing of uremic patients." Klin Wochenschr 48 (1970):  1052|Lloyd-Mostyn R, Lord I "Ototoxicity of intravenous furosemide." Lancet 2 (1971):  1156|Schwartz G "Ototoxicity induced by furosemide." N Engl J Med 282 (1970):  1413|Venkateswaran P "Transient deafness from high doses of furosemide." Br Med J 4 (1971):  113|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Schneider WJ, Becker EL "Acute transient hearing loss after ethacrynic acid therapy." Arch Intern Med 117 (1966):  715-7|Matz GJ, Beal DD, Krames L "Ototoxicity of ethacrynic acid. Demonstrated in a human temporal bone." Arch Otolaryngol 90 (1969):  152-5|Rybak LP "Ototoxicity of ethacrynic acid (a persistent clinical problem)." J Laryngol Otol 102 (1988):  518-20|Meriwether WD, Mangi RJ, Serpick AA "Deafness following standard intravenous dose of ethacrynic acid." JAMA 216 (1971):  795-8|Merrill JP "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Chaffee WG Jr "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Ng PS, Conley CE, Ing TS "Deafness after ethacrynic acid." Lancet 1 (1969):  673-4|Matz GJ "The ototoxic effects of ethacrynic acid in man and animals." Laryngoscope 86 (1976):  1065-86|Quick CA, Duvall AJ 3d "Early changes in the cochlear duct from ethacrynic acid: an electronmicroscopie evaluation." Laryngoscope 80 (1970):  954-65|Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979):  309-19|Gomolin IH, Garschick E "Ethacrynic acid-induced deafness accompanied by nystagmus." N Engl J Med 303 (1980):  702|Homer MJ "Deafness after ethacrynic acid." N Engl J Med 285 (1971):  1152|David DS, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328-9|Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978):  791-800|Rybak LP "Ototoxicity of loop diuretics." Otolaryngol Clin North Am 26 (1993):  829-44|Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971):  359-63|Arnold W, Nadol JB Jr, Weidauer H "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh) 91 (1981):  399-414|Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973):  325-36|Beauchamp GD, Crouch TC "Deafness. Review of intravenous ethacrynic acid." J Kans Med Soc 76 (1975):  166-8,180|Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976):  561-70|Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50621, 24890, 'Etacrynic acid', 'Kidney Diseases', 'Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction.  These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss).  Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function.  Prolongation of the dosing intervals may be appropriate to prevent drug accumulation.  The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow.  If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.', '3', 'Huang CM, Atkinson AJ, Levin M, et al. "Pharmacokinetics of furosemide in advanced renal failure." Clin Pharmacol Ther 16 (1974):  659-66|Cutler RE, Forrey AW, Christopher TG, Kimpel BM "Pharmacokinetics of furosemide in normal subjects and functionally anephric patients." Clin Pharmacol Ther 15 (1974):  588-96|Rose HJ, O''Malley K, Pruitt AW "Depression of renal clearance of furosemide in man by azotemia." Clin Pharmacol Ther 21 (1976):  141-6|Beermann B, Dalen E, Lindstrom B "Elimination of furosemide in healthy subjects and in those with renal failure." Clin Pharmacol Ther 22 (1977):  70-8|Tilstone WJ, Fine A "Furosemide kinetics in renal failure." Clin Pharmacol Ther 23 (1978):  644-50|Rane A, Villeneuve JP, Stone WJ, et al. "Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia." Clin Pharmacol Ther 24 (1978):  199-207|Andreasen F, Hansen HE, Mikkelsen E "Pharmacokinetics of furosemide in anephric patients and in normal subjects." Eur J Clin Pharmacol 13 (1978):  41-8|Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P "Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide." Eur J Clin Pharmacol 20 (1981):  27-33|Donatucci CF, Deshon GE, Wade CE, Hunt M "Furosemide-induced disturbances of renal function in patients undergoing TURP." Urology 35 (1990):  295-300|Keller E, Hoppe-Seyler G, Schollmeyer P "Disposition and diuretic effect of furosemide in the nephrotic syndrome." Clin Pharmacol Ther 32 (1982):  442-9|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Pentikainen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Penttila A "Bumetanide kinetics in renal failure." Clin Pharmacol Ther 37 (1985):  582-8|Marcantonio LA, Auld WH, Murdoch WR, Purohit R, Skellern GG, Howes CA "The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease." Br J Clin Pharmacol 15 (1983):  245-52|Berg KJ, Tromsdal A, Wideroe TE "Diuretic action of bumetanide in advanced chronic renal insufficiency." Eur J Clin Pharmacol 9 (1976):  265-75|Lowenthal DT, Dickerman D "The use of diuretics in varying degrees of renal impairment: an overview." Clin Exp Hypertens A 5 (1983):  297-307|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Kaye M, Dufresne L, McDade D "Ethacrynic acid in acute renal failure." Lancet 1 (1968):  1255|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Risler T, Schwab A, Kramer B, Braun N, Erley C "Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure." Cardiology 84 (1994):  155-61|Russo D, Minutolo R, Andreucci VE "Role of loop diuretics in chronic renal failure." Cardiology 84 (1994):  162-70', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50622, 24890, 'Etacrynic acid', 'Diabetes Mellitus', 'Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests.  Rarely, precipitation of diabetes mellitus has been reported.  Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988):  427-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Gray GM "Drugs, malnutrition, and carbohydrate absorption." Am J Clin Nutr 26 (1973):  121-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993):  557-9|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974):  85-90|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50623, 24890, 'Etacrynic acid', 'Hyperuricemia', 'Loop diuretics may decrease the rate of uric acid excretion.  Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with loop diuretics should be administered cautiously in such patients.', '2', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50624, 0, 'Ethionamide', 'Liver Diseases', 'The use of ethionamide is contraindicated in patients with severe liver damage.  Like many other antituberculous agents, ethionamide is hepatotoxic.  Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide.  Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus.  Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes.  Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.', '3', 'Bennett JE, Mandell GL, Dolin R, eds.. "Mandell, Douglas and Bennett''s Principles and Practice of Infectious Diseases." New York, NY: Churchill Livingston 1 (1995):|"Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50625, 0, 'Ethionamide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent.  Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism.  Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.', '3', '"Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50626, 0, 'Ethionamide', 'Diabetes Mellitus', 'The use of ethionamide has occasionally been associated with poor diabetic control.  Patients with diabetes mellitus should be monitored more closely during therapy with ethionamide, and their antidiabetic regimen adjusted accordingly.', '2', 'Bennett JE, Mandell GL, Dolin R, eds.. "Mandell, Douglas and Bennett''s Principles and Practice of Infectious Diseases." New York, NY: Churchill Livingston 1 (1995):|"Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50627, 0, 'Ethchlorvynol', 'Alcoholic Intoxication', 'Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of these agents may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50628, 0, 'Ethchlorvynol', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50629, 0, 'Ethchlorvynol', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E "Tolerance and withdrawal with zolpidem." Lancet 342 (1993):  374-5|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Gericke CA, Ludolph AC "Chronic abuse of zolpidem." JAMA 272 (1994):  1721-2|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50630, 0, 'Ethchlorvynol', 'Porphyrias', 'The use of ethchlorvynol is contraindicated in patients with a history of porphyria.  Ethchlorvynol has been reported to precipitate acute attacks of porphyria in susceptible patients.', '3', '"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50631, 0, 'Ethchlorvynol', 'Liver Diseases', 'Ethchlorvynol is thought to be metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Patients with renal and/or liver disease may be at greater risk for adverse effects from ethchlorvynol, including central nervous system and respiratory depression, due to decreased drug clearance.  Therapy with ethchlorvynol should be administered cautiously in patients with impaired renal and/or hepatic function.  In one study, patients with renal impairment experienced excessive drowsiness following repeated dosing of the drug, presumably due to its accumulation in the plasma.', '3', 'Dawborn JK, Turner A, Pattison G "Ethchlorvynol as a sedative in patients with renal failure." Med J Aust Sept (1972):  702-4|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50632, 0, 'Ethchlorvynol', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50633, 0, 'Ethchlorvynol', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|Lheureux P, Debailleul G, De Witte O, Askenasi R "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol 9 (1990):  105-7|Murciano D, Aubier M, Palacios S, Parients R "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)." Chest 97 Suppl (1990):  s51-2|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Biban P, Baraldi E, Pettennazzo A, Filippone M, Zacchello F "Adverse effect of chloral hydrate in two young children with obstructive sleep apnea." Pediatrics 92 (1993):  461-3|Greenberg SB, Faerber EN "Respiratory insufficiency following chloral hydrate sedation in two children with Leigh disease (subacute necrotizing encephalomyelopathy)." Pediatr Radiol 20 (1990):  287-8|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50634, 4440, 'Ethosuximide', 'Hematologic Diseases', 'Hematologic toxicities, some with fatal outcome, have been associated with the use of succinimide anticonvulsants.  Leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia, pancytopenia, and eosinophilia have been reported.  Therapy with succinimide anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow suppression.  Complete blood counts, including platelets, should be performed prior to initiating therapy and periodically during therapy.  Marked depression of blood counts may be indication for withdrawal of succinimide therapy.', '3', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Seip M "Aplastic anemia during ethosuximide medication. Treatment with bolus- methylprednisolone." Acta Paediatr Scand 72 (1983):  927-9|Massey GV, Dunn NL, Heckel JL, Myer EC, Russell EC "Aplastic anemia following therapy for absence seizures with ethosuximide." Pediatr Neurol 11 (1994):  59-61|"Product Information. Zarontin (ethosuximide)." Parke-Davis  (2001):|"Product Information. Milontin (phensuximide)." Parke-Davis  (2001):|"Product Information. Celontin (methsuximide)." Parke-Davis', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50635, 18605, 'Ethosuximide', 'Hematologic Diseases', 'Hematologic toxicities, some with fatal outcome, have been associated with the use of succinimide anticonvulsants.  Leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia, pancytopenia, and eosinophilia have been reported.  Therapy with succinimide anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow suppression.  Complete blood counts, including platelets, should be performed prior to initiating therapy and periodically during therapy.  Marked depression of blood counts may be indication for withdrawal of succinimide therapy.', '3', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Seip M "Aplastic anemia during ethosuximide medication. Treatment with bolus- methylprednisolone." Acta Paediatr Scand 72 (1983):  927-9|Massey GV, Dunn NL, Heckel JL, Myer EC, Russell EC "Aplastic anemia following therapy for absence seizures with ethosuximide." Pediatr Neurol 11 (1994):  59-61|"Product Information. Zarontin (ethosuximide)." Parke-Davis  (2001):|"Product Information. Milontin (phensuximide)." Parke-Davis  (2001):|"Product Information. Celontin (methsuximide)." Parke-Davis', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50636, 4440, 'Ethosuximide', 'Liver Diseases', 'Succinimide anticonvulsants have produced morphological and functional changes in the liver of animals.  In humans, abnormalities in liver and renal function studies have been reported.  Therapy with succinimide anticonvulsants should be administered with extreme caution in patients with known hepatic or renal diseases.  Periodic urinalysis and liver function tests are recommended for all patients treated with these drugs.', '3', 'Silverman SH, Gribetz D, Rausen AR "Nephrotic syndrome associated with ethosuccimide." Am J Dis Child 132 (1978):  99|Coulter DL "Ethosuximide-induced liver dysfunction." Arch Neurol 40 (1983):  393-4|Korinthenberg R, Wehrle L, Zimmerhackl LB "Renal tubular dysfunction following treatment with anti-epileptic drugs." Eur J Pediatr 153 (1994):  855-8|"Product Information. Zarontin (ethosuximide)." Parke-Davis  (2001):|"Product Information. Milontin (phensuximide)." Parke-Davis  (2001):|"Product Information. Celontin (methsuximide)." Parke-Davis', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50637, 18605, 'Ethosuximide', 'Liver Diseases', 'Succinimide anticonvulsants have produced morphological and functional changes in the liver of animals.  In humans, abnormalities in liver and renal function studies have been reported.  Therapy with succinimide anticonvulsants should be administered with extreme caution in patients with known hepatic or renal diseases.  Periodic urinalysis and liver function tests are recommended for all patients treated with these drugs.', '3', 'Silverman SH, Gribetz D, Rausen AR "Nephrotic syndrome associated with ethosuccimide." Am J Dis Child 132 (1978):  99|Coulter DL "Ethosuximide-induced liver dysfunction." Arch Neurol 40 (1983):  393-4|Korinthenberg R, Wehrle L, Zimmerhackl LB "Renal tubular dysfunction following treatment with anti-epileptic drugs." Eur J Pediatr 153 (1994):  855-8|"Product Information. Zarontin (ethosuximide)." Parke-Davis  (2001):|"Product Information. Milontin (phensuximide)." Parke-Davis  (2001):|"Product Information. Celontin (methsuximide)." Parke-Davis', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50638, 4440, 'Ethosuximide', 'Lupus Erythematosus, Systemic', 'Cases of systemic lupus erythematosus (SLE) have been reported in association with the use of succinimide anticonvulsants, primarily ethosuximide.  Some of the patients recovered promptly following discontinuation of the drug, while others continued to have active disease long after.  Therapy with succinimide anticonvulsants should be administered cautiously in patients with a history of SLE.', '3', 'Teoh PC, Chan HL "Lupus-scleroderma syndrome induced by ethosuximide." Arch Dis Child 50 (1975):  658-61|Beernink DH, Miller JJ 3d "Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children." J Pediatr 82 (1973):  113-7|Alter BP "Systemic lupus erythematosus and ethosuccimide." J Pediatr 77 (1970):  1093-5|Dabbous IA, Idriss HM "Occurrence of systemic lupus erythematosus in association with ethosuccimide therapy. Case report." J Pediatr 76 (1970):  617-20|Livingston S, Rodriguez H, Greene CA, Pauli LL "Systemic lupus erythematosus. Occurrence in association with ethosuximide therapy." JAMA 203 (1968):  731-2|Singsen BH, Fishman L, Hanson V "Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants." Pediatrics 57 (1976):  529-34|"Product Information. Zarontin (ethosuximide)." Parke-Davis  (2001):|"Product Information. Milontin (phensuximide)." Parke-Davis  (2001):|"Product Information. Celontin (methsuximide)." Parke-Davis', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50639, 18605, 'Ethosuximide', 'Lupus Erythematosus, Systemic', 'Cases of systemic lupus erythematosus (SLE) have been reported in association with the use of succinimide anticonvulsants, primarily ethosuximide.  Some of the patients recovered promptly following discontinuation of the drug, while others continued to have active disease long after.  Therapy with succinimide anticonvulsants should be administered cautiously in patients with a history of SLE.', '3', 'Teoh PC, Chan HL "Lupus-scleroderma syndrome induced by ethosuximide." Arch Dis Child 50 (1975):  658-61|Beernink DH, Miller JJ 3d "Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children." J Pediatr 82 (1973):  113-7|Alter BP "Systemic lupus erythematosus and ethosuccimide." J Pediatr 77 (1970):  1093-5|Dabbous IA, Idriss HM "Occurrence of systemic lupus erythematosus in association with ethosuccimide therapy. Case report." J Pediatr 76 (1970):  617-20|Livingston S, Rodriguez H, Greene CA, Pauli LL "Systemic lupus erythematosus. Occurrence in association with ethosuximide therapy." JAMA 203 (1968):  731-2|Singsen BH, Fishman L, Hanson V "Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants." Pediatrics 57 (1976):  529-34|"Product Information. Zarontin (ethosuximide)." Parke-Davis  (2001):|"Product Information. Milontin (phensuximide)." Parke-Davis  (2001):|"Product Information. Celontin (methsuximide)." Parke-Davis', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50640, 4440, 'Ethosuximide', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50641, 18605, 'Ethosuximide', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50642, 4440, 'Ethosuximide', 'Diseases requiring dialysis', 'Ethosuximide has been shown to be removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Marbury TC, Lee CSC, Perchalski RJ, Wilder BJ "Hemodialysis clearance of ethosuximide in patients with chronic renal disease." Am J Hosp Pharm 38 (1981):  1757-60', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50643, 18605, 'Ethosuximide', 'Diseases requiring dialysis', 'Ethosuximide has been shown to be removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'Marbury TC, Lee CSC, Perchalski RJ, Wilder BJ "Hemodialysis clearance of ethosuximide in patients with chronic renal disease." Am J Hosp Pharm 38 (1981):  1757-60', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50644, 29189, 'Abemaciclib', 'Liver Diseases', 'The dosing frequency of abemaciclib should be reduced to once daily when it is administered to patients with severe hepatic impairment (Child-Pugh C).  No dosage adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh A or B).  Hepatotoxicity has been reported with the use of abemaciclib.  It is recommended to monitor liver function tests prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or Grade 3 or 4, hepatic transaminase elevation.', '3', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50645, 29190, 'Abemaciclib', 'Liver Diseases', 'The dosing frequency of abemaciclib should be reduced to once daily when it is administered to patients with severe hepatic impairment (Child-Pugh C).  No dosage adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh A or B).  Hepatotoxicity has been reported with the use of abemaciclib.  It is recommended to monitor liver function tests prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or Grade 3 or 4, hepatic transaminase elevation.', '3', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50646, 29191, 'Abemaciclib', 'Liver Diseases', 'The dosing frequency of abemaciclib should be reduced to once daily when it is administered to patients with severe hepatic impairment (Child-Pugh C).  No dosage adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh A or B).  Hepatotoxicity has been reported with the use of abemaciclib.  It is recommended to monitor liver function tests prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or Grade 3 or 4, hepatic transaminase elevation.', '3', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50647, 29192, 'Abemaciclib', 'Liver Diseases', 'The dosing frequency of abemaciclib should be reduced to once daily when it is administered to patients with severe hepatic impairment (Child-Pugh C).  No dosage adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh A or B).  Hepatotoxicity has been reported with the use of abemaciclib.  It is recommended to monitor liver function tests prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or Grade 3 or 4, hepatic transaminase elevation.', '3', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50648, 29189, 'Abemaciclib', 'Diarrhea', 'Diarrhea, sometimes associated with dehydration and infection, has occurred in patients receiving abemaciclib.  Diarrhea incidence was greatest during the first month of abemaciclib dosing.  Care should be exercised when treating patients with symptoms of diarrhea.  Treatment discontinuation may be required for Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization.  Resume treatment at the next lower dose once toxicity resolves to <= Grade 1 diarrhea.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50649, 29190, 'Abemaciclib', 'Diarrhea', 'Diarrhea, sometimes associated with dehydration and infection, has occurred in patients receiving abemaciclib.  Diarrhea incidence was greatest during the first month of abemaciclib dosing.  Care should be exercised when treating patients with symptoms of diarrhea.  Treatment discontinuation may be required for Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization.  Resume treatment at the next lower dose once toxicity resolves to <= Grade 1 diarrhea.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50650, 29191, 'Abemaciclib', 'Diarrhea', 'Diarrhea, sometimes associated with dehydration and infection, has occurred in patients receiving abemaciclib.  Diarrhea incidence was greatest during the first month of abemaciclib dosing.  Care should be exercised when treating patients with symptoms of diarrhea.  Treatment discontinuation may be required for Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization.  Resume treatment at the next lower dose once toxicity resolves to <= Grade 1 diarrhea.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50651, 29192, 'Abemaciclib', 'Diarrhea', 'Diarrhea, sometimes associated with dehydration and infection, has occurred in patients receiving abemaciclib.  Diarrhea incidence was greatest during the first month of abemaciclib dosing.  Care should be exercised when treating patients with symptoms of diarrhea.  Treatment discontinuation may be required for Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization.  Resume treatment at the next lower dose once toxicity resolves to <= Grade 1 diarrhea.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50652, 29189, 'Abemaciclib', 'Lung Diseases, Interstitial', 'Patients treated with abemaciclib have reported severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD/pneumonitis such as, hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams.  Dose interruption or dose reduction is recommended for patients who develop persistent or recurrent Grade 2 ILD/pneumonitis.  Permanently discontinue therapy in all patients with Grade 3 or 4 ILD or pneumonitis.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50653, 29190, 'Abemaciclib', 'Lung Diseases, Interstitial', 'Patients treated with abemaciclib have reported severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD/pneumonitis such as, hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams.  Dose interruption or dose reduction is recommended for patients who develop persistent or recurrent Grade 2 ILD/pneumonitis.  Permanently discontinue therapy in all patients with Grade 3 or 4 ILD or pneumonitis.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50654, 29191, 'Abemaciclib', 'Lung Diseases, Interstitial', 'Patients treated with abemaciclib have reported severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD/pneumonitis such as, hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams.  Dose interruption or dose reduction is recommended for patients who develop persistent or recurrent Grade 2 ILD/pneumonitis.  Permanently discontinue therapy in all patients with Grade 3 or 4 ILD or pneumonitis.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50655, 29192, 'Abemaciclib', 'Lung Diseases, Interstitial', 'Patients treated with abemaciclib have reported severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD/pneumonitis such as, hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams.  Dose interruption or dose reduction is recommended for patients who develop persistent or recurrent Grade 2 ILD/pneumonitis.  Permanently discontinue therapy in all patients with Grade 3 or 4 ILD or pneumonitis.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50656, 29189, 'Abemaciclib', 'Neutropenia', 'Neutropenia, including febrile neutropenia has occurred in patients receiving abemaciclib.  Care should be exercised when prescribing this agent to patients with preexisting neutropenia.  It is recommended to monitor complete blood counts prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50657, 29190, 'Abemaciclib', 'Neutropenia', 'Neutropenia, including febrile neutropenia has occurred in patients receiving abemaciclib.  Care should be exercised when prescribing this agent to patients with preexisting neutropenia.  It is recommended to monitor complete blood counts prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50658, 29191, 'Abemaciclib', 'Neutropenia', 'Neutropenia, including febrile neutropenia has occurred in patients receiving abemaciclib.  Care should be exercised when prescribing this agent to patients with preexisting neutropenia.  It is recommended to monitor complete blood counts prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50659, 29192, 'Abemaciclib', 'Neutropenia', 'Neutropenia, including febrile neutropenia has occurred in patients receiving abemaciclib.  Care should be exercised when prescribing this agent to patients with preexisting neutropenia.  It is recommended to monitor complete blood counts prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50660, 29189, 'Abemaciclib', 'Venous Thromboembolism', 'Venous thromboembolic events have been reported with the use of abemaciclib.  Care should be exercised when using this agent in patients with risk factors or history of venous thromboembolic events.  It is recommended to monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50661, 29190, 'Abemaciclib', 'Venous Thromboembolism', 'Venous thromboembolic events have been reported with the use of abemaciclib.  Care should be exercised when using this agent in patients with risk factors or history of venous thromboembolic events.  It is recommended to monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50662, 29191, 'Abemaciclib', 'Venous Thromboembolism', 'Venous thromboembolic events have been reported with the use of abemaciclib.  Care should be exercised when using this agent in patients with risk factors or history of venous thromboembolic events.  It is recommended to monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50663, 29192, 'Abemaciclib', 'Venous Thromboembolism', 'Venous thromboembolic events have been reported with the use of abemaciclib.  Care should be exercised when using this agent in patients with risk factors or history of venous thromboembolic events.  It is recommended to monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate.', '2', '"Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50664, 29189, 'Abemaciclib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50665, 29190, 'Abemaciclib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50666, 29191, 'Abemaciclib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50667, 29192, 'Abemaciclib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50668, 0, 'Etravirine', 'Liver Diseases', 'Etravirine is primarily metabolized by the liver.  No dose adjustment of etravirine is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.  Caution is recommended when using this agent in patients with severe hepatic impairment (Child-Pugh Class C) as the pharmacokinetics of etravirine have not been evaluated in these patients.', '2', '"Product Information. Intelence (etravirine)." Ortho Biotech Inc  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50669, 0, 'Etelcalcetide', 'Arrhythmias, Cardiac', 'The use of etelcalcetide lowers serum calcium and can lead to hypocalcemia, sometimes severe.  A decrease in serum calcium can cause paresthesias, myalgias, muscle spasms, seizures, QT interval prolongation, and ventricular arrhythmia.  Patients with congenital long QT syndrome, history of QT interval prolongation, family history of long QT syndrome or sudden cardiac death, and other conditions that predispose to QT interval prolongation and ventricular arrhythmia may be at increased risk for QT interval prolongation and ventricular arrhythmias if they develop hypocalcemia.  Closely monitor corrected serum calcium and QT interval in patients at risk receiving etelcalcetide.', '2', '"Product Information. Parsabiv (etelcalcetide)." Amgen USA  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50670, 0, 'Etelcalcetide', 'Peptic Ulcer Hemorrhage', 'The use of etelcalcetide may increase the risk of upper gastrointestinal (GI) bleeding.  Patients with risks factors for upper GI bleeding (such as known gastritis, esophagitis, ulcers, or severe vomiting) may be at increased risk for GI bleeding while receiving etelcalcetide treatment.  It is recommended to monitor patients for worsening of GI adverse reactions such as nausea and vomiting and for signs and symptoms of GI bleeding and ulcerations during therapy with etelcalcetide.  Promptly evaluate and treat any suspected GI bleeding according to medical guidelines.', '2', '"Product Information. Parsabiv (etelcalcetide)." Amgen USA  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50671, 0, 'Etelcalcetide', 'Heart Failure', 'The use of etelcalcetide may cause hypotension, congestive heart failure, and decreased myocardial performance and worsening heart failure.  Reductions in corrected serum calcium may be associated with congestive heart failure.  Close monitoring is recommended for worsening signs and symptoms of heart failure.', '2', '"Product Information. Parsabiv (etelcalcetide)." Amgen USA  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50672, 0, 'Etelcalcetide', 'Seizures', 'The use of etelcalcetide may cause seizures due to significant reductions in corrected serum calcium.  Patients with a history of seizure disorder may be at increased risk for seizures if they develop hypocalcemia due to etelcalcetide therapy.  It is recommended to measure corrected serum calcium prior to and within 1 week after initiation or dose adjustment and every 4 weeks during treatment.  Do not initiate in patients if the corrected serum calcium is less than the lower limit of normal.  Close monitor corrected serum calcium in patients with seizure disorders receiving etelcalcetide.  Dose reduction or discontinuation of therapy may be necessary if corrected serum calcium falls below the lower limit of normal or symptoms of hypocalcemia develop.', '2', '"Product Information. Parsabiv (etelcalcetide)." Amgen USA  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50673, 24890, 'Etidronic acid', 'Osteomalacia', 'The use of etidronate (for the treatment of Paget''s disease or the treatment/prevention of heterotopic ossification) is contraindicated in patients with clinically overt osteomalacia.  Etidronate can inhibit bone mineralization, which has resulted in osteomalacia and bone fractures in some patients.  Accumulation of unmineralized osteoid is usually noticeable during prolonged, continuous use of high dosages (10 to 20 mg/kg/day) but may occur at lower dosages when use exceeds 6 months.  The newer bisphosphonates (e.g., alendronate, pamidronate, risedronate, and tiludronate) do not cause mineralization defects and may be more appropriate for patients with osteomalacia, although clinical data may be lacking for the treatment of some conditions for which etidronate is used.', '3', 'Mautalen C, Gonzalez D, Blumenfeld EL, Santini Araujo E, Schajowicz F "Spontaneous fractures of uninvolved bones in patients with Paget''s disease during unduly prolonged treatment with disodium etidronate (EHDP)." Clin Orthop Jun (1986):  150-5|Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT "Focal osteomalacia due to low-dose diphosphonate therapy in Paget''s disease." Lancet 1 (1984):  821-4|Evans RA, Dunstan CR, Hills E, Wong SY "Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget''s disease of bone." Aust N Z J Med 13 (1983):  277-9|"Product Information. Didronel I.V. (etidronate)." MGI Pharma Inc  (2022):|"Product Information. Didronel (etidronate)." Procter and Gamble Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50674, 24890, 'Etidronic acid', 'Gastrointestinal Diseases', 'Etidronate administered orally may cause local irritation of the upper gastrointestinal mucosa.  Its use is contraindicated in patients with esophageal abnormalities that delay esophageal emptying such as achalasia or strictures.  Etidronate should be used with caution in patients with active upper gastrointestinal problems, such as Barrett''s esophagus, dysphagia, gastritis, duodenitis, ulcers, etc, as cases of erosions, bleeding and perforation have been reported.  Patients should be instructed to discontinue treatment immediately and seek medical attention if they develop dysphagia, retrosternal pain, or new or worsening heartburn.', '3', '"Product Information. Didronel I.V. (etidronate)." MGI Pharma Inc  (2022):|"Product Information. Didronel (etidronate)." Procter and Gamble Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50675, 24890, 'Etidronic acid', 'Kidney Diseases', 'Etidronate is eliminated intact by the kidney.  There is no experience to specifically make recommendations in patients with impaired renal function.  Etidronate dosage should be reduced when reductions in glomerular filtration rates are present.  Patients with renal impairment should be closely monitored.', '2', '"Product Information. Didronel I.V. (etidronate)." MGI Pharma Inc  (2022):|"Product Information. Didronel (etidronate)." Procter and Gamble Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50676, 4446, 'Etodolac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50677, 4447, 'Etodolac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50678, 4448, 'Etodolac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50679, 4449, 'Etodolac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50680, 22198, 'Etodolac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50681, 23254, 'Etodolac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50682, 25491, 'Etodolac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50683, 25492, 'Etodolac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50684, 4446, 'Etodolac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50685, 4447, 'Etodolac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50686, 4448, 'Etodolac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50687, 4449, 'Etodolac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50688, 22198, 'Etodolac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50689, 23254, 'Etodolac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50690, 25491, 'Etodolac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50691, 25492, 'Etodolac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Anaprox (naproxen)." Roche Laboratories  (2006):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50692, 4446, 'Etodolac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50693, 4447, 'Etodolac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50694, 4448, 'Etodolac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50695, 4449, 'Etodolac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50696, 22198, 'Etodolac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50697, 23254, 'Etodolac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50698, 25491, 'Etodolac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50699, 25492, 'Etodolac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50700, 4446, 'Etodolac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50701, 4447, 'Etodolac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50702, 4448, 'Etodolac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50703, 4449, 'Etodolac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50704, 22198, 'Etodolac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50705, 23254, 'Etodolac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50706, 25491, 'Etodolac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50707, 25492, 'Etodolac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50708, 4446, 'Etodolac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50709, 4447, 'Etodolac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50710, 4448, 'Etodolac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50711, 4449, 'Etodolac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50712, 22198, 'Etodolac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50713, 23254, 'Etodolac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50714, 25491, 'Etodolac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50715, 25492, 'Etodolac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50716, 4446, 'Etodolac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50717, 4447, 'Etodolac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50718, 4448, 'Etodolac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50719, 4449, 'Etodolac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50720, 22198, 'Etodolac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50721, 23254, 'Etodolac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50722, 25491, 'Etodolac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50723, 25492, 'Etodolac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Ponstel (mefenamic acid)." Pfizer U.S. Pharmaceuticals Group  (2006):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50724, 4446, 'Etodolac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50725, 4447, 'Etodolac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50726, 4448, 'Etodolac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50727, 4449, 'Etodolac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50728, 22198, 'Etodolac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50729, 23254, 'Etodolac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50730, 25491, 'Etodolac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50731, 25492, 'Etodolac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50732, 4446, 'Etodolac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50733, 4447, 'Etodolac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50734, 4448, 'Etodolac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50735, 4449, 'Etodolac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50736, 22198, 'Etodolac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50737, 23254, 'Etodolac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50738, 25491, 'Etodolac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50739, 25492, 'Etodolac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50740, 4446, 'Etodolac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50741, 4447, 'Etodolac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50742, 4448, 'Etodolac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50743, 4449, 'Etodolac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50744, 22198, 'Etodolac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50745, 23254, 'Etodolac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50746, 25491, 'Etodolac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50747, 25492, 'Etodolac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Toradol (ketorolac)." Roche Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50748, 4446, 'Etodolac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50749, 4447, 'Etodolac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50750, 4448, 'Etodolac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50751, 4449, 'Etodolac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50752, 22198, 'Etodolac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50753, 23254, 'Etodolac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50754, 25491, 'Etodolac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50755, 25492, 'Etodolac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50756, 4446, 'Etodolac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50757, 4447, 'Etodolac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50758, 4448, 'Etodolac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50759, 4449, 'Etodolac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50760, 22198, 'Etodolac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50761, 23254, 'Etodolac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50762, 25491, 'Etodolac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50763, 25492, 'Etodolac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50764, 4446, 'Etodolac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50765, 4447, 'Etodolac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50766, 4448, 'Etodolac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50767, 4449, 'Etodolac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50768, 22198, 'Etodolac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50769, 23254, 'Etodolac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50770, 25491, 'Etodolac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50771, 25492, 'Etodolac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50772, 24890, 'Aminocaproic acid', 'Muscular Diseases', 'Skeletal muscle toxicity ranging from mild myalgia to rhabdomyolysis has been reported rarely during prolonged administration of aminocaproic acid.  Therapy with aminocaproic acid should be administered cautiously in patients with or predisposed to myopathy.  Clinical monitoring of muscle enzymes (particularly CPK) are recommended.', '3', '"Product Information. Amicar (aminocaproic acid)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50773, 24890, 'Aminocaproic acid', 'Kidney Diseases', 'Aminocaproic acid is primarily eliminated by the kidney.  Approximately 65% of aminocaproic acid is excreted unchanged in the urine.  Serum concentrations of aminocaproic acid can be increased in patients with renal impairment.  Therapy with aminocaproic acid should be administered with extreme caution in patients with upper urinary tract bleeding.  Glomerular capillary thrombosis or clots in the renal pelvis and ureters have occurred in patients with upper urinary tract bleeding during aminocaproic acid therapy.  Clinical monitoring of renal function, clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.', '3', '"Product Information. Amicar (aminocaproic acid)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50774, 24890, 'Aminocaproic acid', 'Disseminated Intravascular Coagulation', 'The use of aminocaproic acid is contraindicated in patients with active intravascular clotting.  Aminocaproic acid should not be used in the presence of disseminated intravascular coagulation (DIC) without concomitant administration of heparin.  Aminocaproic acid inhibits plasminogen activators and, to a lesser extent, plasmin activity, resulting in decreased fibrinolysis.  Clinical monitoring of clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.', '3', '"Product Information. Amicar (aminocaproic acid)." Immunex Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50775, 4432, 'Ethambutol', 'Optic Neuritis', 'Ethambutol is contraindicated in patients with known optic neuritis unless clinical judgement determines that it may be used.  Ethambutol can produce decreases in visual acuity which appear to be due to optic neuritis.  This may be related to dose and duration of treatment, and is generally reversible when administration of the drug is discontinued promptly.  However, irreversible blindness has been reported.  Ethambutol should not be used in patients who are unable to identify and report visual side effects or changes in vision such as young children or unconscious patients.  It should be administered cautiously and only after careful consideration of risks and benefits in patients with preexisting visual defects such as cataracts, diabetic retinopathy, or recurrent inflammatory conditions of the eye.  Ophthalmologic testing of visual acuity, visual field, and color discrimination is required before and during treatment.  However, visual changes may be difficult to evaluate in some cases, since they may be related to the underlying disease rather than the drug.', '3', 'Lees AW, Allan GW, Smith J, et al. "Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy." Tubercle 52 (1971):  182-90|Polak BC, Leys M, van Lith GH "Blue-yellow colour vision changes as early symptoms of ethambutol oculotoxicity." Ophthalmology 191 (1985):  223-6|Chatterjee VK, Buchanan DR, Friedmann AI, Green M "Ocular toxicity following ethambutol in standard dosage." Br J Dis Chest 80 (1986):  288-91|Joubert PH, Strobele JG, Ogle CW, van der Merwe CA "Subclinical impairment of colour vision in patients receiving ethambutol." Br J Clin Pharmacol 21 (1986):  213-6|DeVita EG, Miao M, Sadun AA "Optic neuropathy in ethambutol-treated renal tuberculosis." J Clin Neuroophthalmol 7 (1987):  77-83|Jimenez-Lucho VE, del Busto R, Odel J "Isoniazid and ethambutol as a cause of optic neuropathy." Eur J Respir Dis 71 (1987):  42-5|Kahana LM "Toxic ocular effects of ethambutol." Can Med Assoc J 137 (1987):  213-6|Bandopadhya P, Dash RJ "Toxic ocular effects of ethambutol." Can Med Assoc J 138 (1988):  493|Schild HS, Fox BC "Rapid-onset reversible ocular toxicity from ethambutol therapy." Am J Med 90 (1991):  404-6|Smith JL "Should ethambutol be barred?" J Clin Neuroophthalmol 7 (1987):  84-6|"Product Information. Myambutol (ethambutol)." Lederle Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50776, 4432, 'Ethambutol', 'Hepatic Insufficiency', 'Liver toxicities including fatalities have been reported when using ethambutol.  Caution is advised, especially if using in patients with hepatic impairment.  Baseline and periodic assessment of hepatic function should be performed.', '2', '"Product Information. Myambutol (ethambutol)." Lederle Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50777, 4432, 'Ethambutol', 'Hyperuricemia', 'Ethambutol may commonly cause hyperuricemia, which has been reported in up to two-thirds of treated patients.  Occasionally, it has led to joint arthralgias and gouty arthritis after 1 to 2 months of therapy.  Serum uric acid levels should be monitored in patients with preexisting hyperuricemia or gout during ethambutol therapy, and appropriate measures (e.g., administration of uricosuric agents) taken to prevent the development or exacerbation of gout.', '2', 'Postlethwaite AE, Bartel AG, Kelley WN "Hyperuricemia due to ethambutol." N Engl J Med 286 (1972):  761-2|Khanna BK "Acute gouty arthritis following ethambutol therapy." Br J Dis Chest 74 (1980):  409-10|Narang RK, Agarwal MC, Raina AK, et al. "Hyperuricaemia induced by ethambutol." Br J Dis Chest 77 (1983):  403-6|Khanna BK, Gupta VP, Singh MP "Ethambutol-induced hyperuricaemia." Tubercle 65 (1984):  195-9|"Product Information. Myambutol (ethambutol)." Lederle Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50778, 4432, 'Ethambutol', 'Kidney Diseases', 'Ethambutol is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from ethambutol, including optic neuritis, due to decreased drug clearance.  Therapy with ethambutol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in moderate renal impairment but should be based on serum levels of ethambutol.', '2', 'Collier J, Joekes AM, Philalithis PE, Thompson FD "Two cases of ethambutol nephrotoxicity." Br Med J 11/06/76 (1976):  1105-6|Stone WJ, Waldron JA, Dixon JH, et al. "Acute diffuse interstitial nephritis related to chemotherapy of tuberculosis." Antimicrob Agents Chemother 10 (1976):  164-72|Garcia-Martin F, Mampaso F, de Arriba G, et al. "Acute interstitial nephritis induced by ethambutol." Nephron 59 (1991):  679-80|Varughese A, Brater DC, Benet LZ, Lee C-S "Ethambutol kinetics in patients with impaired renal function." Am Rev Respir Dis 134 (1986):  34-8|Insel J, Mirvis DM, Boland MJ, Cinquegrani MP, Shanes J, Rubin SA, Whalen JJ "A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure." Clin Pharmacol Ther 45 (1989):  312-20|De Feo P, Torlone E, Perriello G, Fanelli C, Epifano L, Di Vincenzo A, Modarelli F, Motolese M, Brunetti P, Bolli GB "Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension." Diabete Metab 18 (1992):  283-8|"Product Information. Myambutol (ethambutol)." Lederle Laboratories  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50779, 2361, 'Everolimus', 'Liver Diseases', 'Everolimus exposure was increased in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment.  In patients with mild or moderate hepatic impairment, a dose reduction is recommended.  Patients with severe hepatic impairment, everolimus may be used at a reduced dose if the desired benefit outweighs the risk.', '3', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50780, 2419, 'Everolimus', 'Liver Diseases', 'Everolimus exposure was increased in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment.  In patients with mild or moderate hepatic impairment, a dose reduction is recommended.  Patients with severe hepatic impairment, everolimus may be used at a reduced dose if the desired benefit outweighs the risk.', '3', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50781, 2420, 'Everolimus', 'Liver Diseases', 'Everolimus exposure was increased in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment.  In patients with mild or moderate hepatic impairment, a dose reduction is recommended.  Patients with severe hepatic impairment, everolimus may be used at a reduced dose if the desired benefit outweighs the risk.', '3', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50782, 13565, 'Everolimus', 'Liver Diseases', 'Everolimus exposure was increased in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment.  In patients with mild or moderate hepatic impairment, a dose reduction is recommended.  Patients with severe hepatic impairment, everolimus may be used at a reduced dose if the desired benefit outweighs the risk.', '3', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50783, 13566, 'Everolimus', 'Liver Diseases', 'Everolimus exposure was increased in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment.  In patients with mild or moderate hepatic impairment, a dose reduction is recommended.  Patients with severe hepatic impairment, everolimus may be used at a reduced dose if the desired benefit outweighs the risk.', '3', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50784, 16172, 'Everolimus', 'Liver Diseases', 'Everolimus exposure was increased in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment.  In patients with mild or moderate hepatic impairment, a dose reduction is recommended.  Patients with severe hepatic impairment, everolimus may be used at a reduced dose if the desired benefit outweighs the risk.', '3', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50785, 16174, 'Everolimus', 'Liver Diseases', 'Everolimus exposure was increased in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment.  In patients with mild or moderate hepatic impairment, a dose reduction is recommended.  Patients with severe hepatic impairment, everolimus may be used at a reduced dose if the desired benefit outweighs the risk.', '3', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50786, 2361, 'Everolimus', 'Kidney Diseases', 'Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with inhibitors of mTOR (mammalian target of rapamycin).  Therapy with these agents should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function.  Renal impairment is not expected to influence drug exposure, and no dosage adjustment is recommended in patients with renal impairment.  Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50787, 2419, 'Everolimus', 'Kidney Diseases', 'Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with inhibitors of mTOR (mammalian target of rapamycin).  Therapy with these agents should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function.  Renal impairment is not expected to influence drug exposure, and no dosage adjustment is recommended in patients with renal impairment.  Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50788, 2420, 'Everolimus', 'Kidney Diseases', 'Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with inhibitors of mTOR (mammalian target of rapamycin).  Therapy with these agents should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function.  Renal impairment is not expected to influence drug exposure, and no dosage adjustment is recommended in patients with renal impairment.  Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50789, 13565, 'Everolimus', 'Kidney Diseases', 'Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with inhibitors of mTOR (mammalian target of rapamycin).  Therapy with these agents should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function.  Renal impairment is not expected to influence drug exposure, and no dosage adjustment is recommended in patients with renal impairment.  Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50790, 13566, 'Everolimus', 'Kidney Diseases', 'Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with inhibitors of mTOR (mammalian target of rapamycin).  Therapy with these agents should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function.  Renal impairment is not expected to influence drug exposure, and no dosage adjustment is recommended in patients with renal impairment.  Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50791, 16172, 'Everolimus', 'Kidney Diseases', 'Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with inhibitors of mTOR (mammalian target of rapamycin).  Therapy with these agents should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function.  Renal impairment is not expected to influence drug exposure, and no dosage adjustment is recommended in patients with renal impairment.  Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50792, 16174, 'Everolimus', 'Kidney Diseases', 'Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with inhibitors of mTOR (mammalian target of rapamycin).  Therapy with these agents should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function.  Renal impairment is not expected to influence drug exposure, and no dosage adjustment is recommended in patients with renal impairment.  Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.', '3', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50793, 2361, 'Everolimus', 'Hematologic Diseases', 'Hematologic abnormalities, including decreased levels of hemoglobin, lymphocytes, platelets, and white blood cell have been observed in patients taking everolimus.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of complete blood count is recommended before starting therapy and periodically thereafter.', '2', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50794, 2419, 'Everolimus', 'Hematologic Diseases', 'Hematologic abnormalities, including decreased levels of hemoglobin, lymphocytes, platelets, and white blood cell have been observed in patients taking everolimus.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of complete blood count is recommended before starting therapy and periodically thereafter.', '2', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50795, 2420, 'Everolimus', 'Hematologic Diseases', 'Hematologic abnormalities, including decreased levels of hemoglobin, lymphocytes, platelets, and white blood cell have been observed in patients taking everolimus.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of complete blood count is recommended before starting therapy and periodically thereafter.', '2', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50796, 13565, 'Everolimus', 'Hematologic Diseases', 'Hematologic abnormalities, including decreased levels of hemoglobin, lymphocytes, platelets, and white blood cell have been observed in patients taking everolimus.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of complete blood count is recommended before starting therapy and periodically thereafter.', '2', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50797, 13566, 'Everolimus', 'Hematologic Diseases', 'Hematologic abnormalities, including decreased levels of hemoglobin, lymphocytes, platelets, and white blood cell have been observed in patients taking everolimus.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of complete blood count is recommended before starting therapy and periodically thereafter.', '2', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50798, 16172, 'Everolimus', 'Hematologic Diseases', 'Hematologic abnormalities, including decreased levels of hemoglobin, lymphocytes, platelets, and white blood cell have been observed in patients taking everolimus.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of complete blood count is recommended before starting therapy and periodically thereafter.', '2', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50799, 16174, 'Everolimus', 'Hematologic Diseases', 'Hematologic abnormalities, including decreased levels of hemoglobin, lymphocytes, platelets, and white blood cell have been observed in patients taking everolimus.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of complete blood count is recommended before starting therapy and periodically thereafter.', '2', '"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50800, 2361, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50801, 2419, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50802, 2420, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50803, 13565, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50804, 13566, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50805, 16172, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50806, 16174, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50807, 2361, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50808, 2419, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50809, 2420, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50810, 13565, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50811, 13566, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50812, 16172, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50813, 16174, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50814, 2361, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50815, 2419, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50816, 2420, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50817, 13565, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50818, 13566, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50819, 16172, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50820, 16174, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50821, 2361, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50822, 2419, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50823, 2420, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50824, 13565, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50825, 13566, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50826, 16172, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50827, 16174, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '"Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories  (2007):|"Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50828, 958, 'Exemestane', 'Osteoporosis', 'Reductions in bone mineral density (BMD) over time are seen with the use of exemestane.  Women with osteoporosis or at risk of osteoporosis should have their BMD formally assessed by densitometry at treatment initiation.  Monitoring for BMD loss is recommended, and treatment for it should be started as appropriate.', '2', '"Product Information. Aromasin (exemestane)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50829, 958, 'Exemestane', 'Vitamin D Deficiency', 'Routine assessment of vitamin D levels prior to the start of aromatase inhibitor treatment should be performed, due to the high prevalence of vitamin D deficiency in women with early breast cancer.  Women with vitamin D deficiency should receive supplementation.', '2', '"Product Information. Aromasin (exemestane)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50830, 15591, 'Exenatide', 'Kidney Failure, Chronic', 'Exenatide should not be used in patients with severe renal impairment (CrCl <30 mL/min) or end-stage renal disease, and should be used with caution in patients with moderate renal impairment and renal transplantation.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50831, 15592, 'Exenatide', 'Kidney Failure, Chronic', 'Exenatide should not be used in patients with severe renal impairment (CrCl <30 mL/min) or end-stage renal disease, and should be used with caution in patients with moderate renal impairment and renal transplantation.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50832, 15591, 'Exenatide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50833, 15592, 'Exenatide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50834, 15591, 'Exenatide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50835, 15592, 'Exenatide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50836, 15591, 'Exenatide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', '"Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc  (2005):|"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50837, 15592, 'Exenatide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', '"Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc  (2005):|"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50838, 0, 'Ethotoin', 'Hematologic Diseases', 'Hematologic toxicities have been associated with the use of hydantoin anticonvulsants, particularly mephenytoin.  Thrombocytopenia, leukopenia, neutropenia, agranulocytosis, pancytopenia and, rarely, hemolytic anemia, aplastic anemia and pure red cell aplasia have been reported.  Therapy with hydantoin anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts, including platelets, should be performed prior to initiating therapy and regularly for several months thereafter.  For mephenytoin, the manufacturer recommends performing counts after 2 weeks on a low dosage, after another 2 weeks when full dosage is reached, then monthly for a year, and every 3 months thereafter.  Marked depression of blood counts may be indication for withdrawal of hydantoin therapy.', '3', 'Schweiger FJ, Kelton JG, Messner H, et al. "Anticonvulsant-induced marrow suppression and immune thrombocytopenia." Acta Haematol 80 (1988):  54-8|Travin M, Macris NT, Block JM, Schwimmer D "Reversible common variable immunodeficiency syndrome induced by phenytoin." Arch Intern Med 149 (1989):  1421-2|Dessypris EN, Redline S, Harris JW, Krantz SB "Diphenylhydantoin-induced pure red cell aplasia." Blood 65 (1985):  789-94|Guerra IC, Fawcett WA, Redmon AH, et al. "Permanent intrinsic B cell immunodeficiency caused by phenytoin hypersensitivity." J Allergy Clin Immunol 77 (1986):  603-8|Eisenstein SJ, Coleman GC "Reversible bone marrow granulomata and fever induced by phenytoin administration." J Fam Pract 29 (1989):  564-5|Cacatian AA, Rando J "Diphenylhydantoin-induced pseudolymphoma syndrome with severe thrombocytopenia." N Y State J Med June (1981):  1085-7|Arbiser JL, Goldstein AM, Gordon D "Thrombocytopenia following administration of phenytoin, dexamethasone and cimetidine: a case report and a potential mechanism." J Intern Med 234 (1993):  91-4|Rawanduzy A, Sarkis A, Rovit RL "Severe phenytoin-induced bone marrow depression and agranulocytosis treated with human recombinant granulocyte-macrophage colony- stimulating factor. Case report." J Neurosurg 79 (1993):  121-4|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|Thompson DF, Gales MA "Drug-induced pure red cell aplasia." Pharmacotherapy 16 (1996):  1002-8|"Product Information. Peganone (ethotoin)." Abbott Pharmaceutical  (2001):|"Product Information. Mesantoin (mephenytoin)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50839, 0, 'Ethotoin', 'Liver Diseases', 'Hydantoin anticonvulsants are primarily metabolized by the liver.  Both metabolic activity and plasma protein binding may be significantly altered in patients with liver disease, resulting in elevated drug levels (total and unbound fraction) and increased risk of toxicity.  Therapy with hydantoin anticonvulsants should be administered cautiously in patients with impaired hepatic function.  Reduced dosages and slower titration may be necessary.  In addition, periodic monitoring of liver function is recommended, since the use of anticonvulsants, including hydantoins, has been associated with hepatotoxicity related to drug hypersensitivity.  Hepatic failure and death have occurred.  Hydantoin therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', 'Affrime M, Reidenberg MM "The protein binding of some drugs in plasma from patients with alcoholic liver disease." Eur J Clin Pharmacol 8 (1975):  267-9|Olsen GD, Bennett WM, Porter GA "Morphine and phenytoin binding to plasma proteins in renal and hepatic failure." Clin Pharmacol Ther 17 (1975):  677-84|Mullick FG, Ishak KG "Hepatic injury associated with diphenylhydantoin therapy: a clinicopathologic study of 20 cases." Am J Clin Pathol 74 (1980):  442-52|Aaron JS, Bank S, Ackert G "Diphenylhydantoin-induced hepatotoxicity." Am J Gastroenterol 80 (1985):  200-2|Gennis MA, Vemuri R, Burns EA, et al. "Familial occurrence of hypersensitivity to phenytoin." Am J Med 91 (1991):  631-4|Taylor JW, Stein MN, Murphy MJ, Mitros FA "Cholestatic liver dysfunction after long-term phenytoin therapy." Arch Neurol 41 (1984):  500-1|Sherertz EF, Jegasothy BV, Lazarus GS "Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis." J Am Acad Dermatol 12 (1985):  178-81|Egerton-Vernon JM, Fisk MJ, Snell AP "Phenytoin-induced hepatotoxicity." N Z Med J 96 (1983):  467-9|Korman LB, Olson MJ "Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction." Clin Pharm 8 (1989):  514-5|Prosser TR, Lander RD "Phenytoin-induced hypersensitivity reactions." Clin Pharm 6 (1987):  728-34|Hooper WD, Bochner F, Eadie MJ, Tyrer JH "Plasma protein binding of diphenylhydantoin: effects of sex hormones, renal and hepatic disease." Clin Pharmacol Ther 15 (1974):  276-82|Roy AK, Mahoney HC, Levine RA "Phenytoin-induced chronic hepatitis." Dig Dis Sci 38 (1993):  740-3|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|Browne TR, Kugler AR, Eldon MA "Pharmacology and pharmacokinetics of fosphenytoin." Neurology 46 (6 supp (1996):  s3-7|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Peganone (ethotoin)." Abbott Pharmaceutical  (2001):|"Product Information. Mesantoin (mephenytoin)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50840, 0, 'Ethotoin', 'Porphyrias', 'The use of phenytoin has rarely been associated with exacerbation of porphyria.  Therapy with phenytoin should be administered cautiously in patients with porphyria.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '3', '"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50841, 0, 'Ethotoin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50842, 0, 'Ethotoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', 'Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981):  1508-12|Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991):  968-70|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Peganone (ethotoin)." Abbott Pharmaceutical  (2001):|"Product Information. Mesantoin (mephenytoin)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50843, 0, 'Ethotoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', 'Goggin T, Gough H, Bissessar A, et al. "A comparative study of the relative effects of anticonvulsant drugs and dietary folate on the red cell folate status of patients with epilepsy." Q J Med 65 (1987):  911-9|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Peganone (ethotoin)." Abbott Pharmaceutical  (2001):|"Product Information. Mesantoin (mephenytoin)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50844, 0, 'Ethotoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', 'Hahn TJ, Hendin BA, Scharp CR, Haddad JG "Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults." N Engl J Med 287 (1972):  900-4|Anast CS "Anticonvulsant drugs and calcium metabolism." N Engl J Med 292 (1975):  587-8|Bell RD, Pak CY, Zerwekh J, et al. "Effect of phenytoin on bone and vitamin d metabolism." Ann Neurol 5 (1979):  374-8|Ronin DI, Wu Y, Sahgal V, MacLean IC "Intractable muscle pain syndrome, osteomalacia, and axonopathy in long-term use of phenytoin." Arch Phys Med Rehabil 72 (1991):  755-8|Schmitt BP, Nordlund DJ, Rodgers LA "Prevalence of hypocalcemia and elevated serum alkaline phosphatase in patients receiving chronic anticonvulsant therapy." J Fam Pract 18 (1984):  873-7|Alderman CP, Hill CL "Abnormal bone mineral metabolism after long-term anticonvulsant treatment." Ann Pharmacother 28 (1994):  47-8|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|Siddiqui MA "Osteomalacia and phenytoin therapy." Ann Intern Med 121 (1994):  550|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50845, 20757, 'Etonogestrel', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Liletta (levonorgestrel)." Actavis Pharma, Inc.  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50846, 20757, 'Etonogestrel', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'Tao LC "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer 68 (1991):  341-7|"Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991):  182-5|Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988):  115-9|Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977):  357-9|Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989):  878-82|Mooney MJ, Nyreen MR, Hall RA, Carter PL "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg 59 (1993):  229-31|Gyorffy EJ, Bredfeldt JE, Black WC "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med 110 (1989):  489-90|Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993):  635-7|Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology 97 (1989):  154-7|Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol 16 (1992):  982-7|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50847, 20757, 'Etonogestrel', 'Breast Neoplasms', 'The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast.  Some supportive data are available for medroxyprogesterone.  Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly.  A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate.  The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years.  Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years.  A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.', '3', 'Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983):  2909-12|"Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984):  1207-8|"Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991):  833-8|Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994):  189-201|Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994):  211-22|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995):  799-807|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50848, 20757, 'Etonogestrel', 'Liver Diseases', 'The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease.  There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease.  However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver.  Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.', '3', 'Utaaker E, Lundgren S, Kvinnsland S, Aakvaag A "Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer." J Steroid Biochem 31 (1988):  437-41|Castegnaro E, Sala G "Pharmacokinetics and metabolism of medroxyprogesterone acetate. Influence of the route of administration and of its physical state." Steroidologia 2 (1971):  13-26|Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984):  109-12|Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992):  69-84|Hendeles SM, Galand N, Schwers J "Metabolism of orally administered D-norgestrel in women." Acta Endocrinol (Copenh) 71 (1972):  557-68|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50849, 20757, 'Etonogestrel', 'Thromboembolism', 'The use of progestogens, in general, is considered by manufacturers to be contraindicated in patients with active thrombophlebitis, cerebrovascular disease, or a current or past history of thromboembolic disorders.  While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant.  Medroxyprogesterone, a common progestational agent, has been shown to produce a hypercoagulable state in high dosages.  Whether or not this effect contributes to the development of thrombotic events is unknown.  However, thrombophlebitis and pulmonary embolism have been reported with megestrol, an antineoplastic and progestational agent.  In addition, an increased risk of nonfatal venous thrombosis has been associated with oral contraceptive combinations containing desogestrel or gestodene relative to those that contain other progestins (e.g., levonorgestrel, norethindrone), suggesting some degree of hemostatic effect by progestogens.', '3', 'Astedt B, Jeppsson S, Pandolfi M "Fibrinolytic activity of veins during use of depot  medroxyprogesterone acetate as a contraceptive." Fertil Steril 23 (1972):  489-92|Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T "Changes in hematologic parameters during treatment with  medroxyprogesterone acetate for breast cancer." Jpn J Cancer Res 82 (1991):  420-5|Fukutomi T, Nanasawa T, Yamamoto H, Adachi I, Watanabe T "The induction of a hypercoagulable state by medroxyprogesterone  acetate in breast cancer patients." Jpn J Surg 20 (1990):  665-70|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50850, 20757, 'Etonogestrel', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50851, 20757, 'Etonogestrel', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50852, 20757, 'Etonogestrel', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50853, 20757, 'Etonogestrel', 'Gallbladder Diseases', 'Etonogestrel might increase the risk of gallbladder disease.  Caution and monitoring of symptoms is suggested in patients with history or active gallbladder disease.', '2', '"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50854, 0, 'Ezogabine', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50855, 0, 'Ezogabine', 'Alcoholism', 'The use ezogabine with alcohol increases the systemic exposure to ezogabine.  Patients should be advised of possible worsening of dose-related adverse reactions if they take ezogabine with alcohol.', '2', '"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50856, 0, 'Ezogabine', 'Hepatic Insufficiency', 'No dosage adjustment is recommended in patients with mild hepatic impairment.  Dosage adjustment is recommended in patients with moderate or severe hepatic impairment.  Close monitoring is recommended.', '2', '"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50857, 0, 'Ezogabine', 'Hyperbilirubinemia', 'Ezogabine has been shown to interfere with clinical laboratory assays of both serum and urine bilirubin, which can result in falsely elevated readings.', '2', '"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50858, 0, 'Ezogabine', 'Long QT Syndrome', 'QT prolongation was observed in patients treated with ezogabine.  It is recommended to monitor the QT interval when ezogabine is used with medicines known to increase QT interval and in patients with known prolonged QT interval, congestive heart failure, ventricular hypertrophy, hypokalemia, or hypomagnesemia.', '2', '"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50859, 0, 'Ezogabine', 'Kidney Diseases', 'Dosage adjustment is recommended in patients with creatinine clearance <50 mL/min or patients with end-stage renal disease receiving hemodialysis.  A supplemental dose is recommended immediately following hemodialysis.  Close monitoring is recommended.', '2', '"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50860, 0, 'Ezogabine', 'Retinal Diseases', 'The use of ezogabine can cause abnormalities of the retina.  Patients should have baseline ophthalmologic testing by an ophthalmic professional and follow-up testing as clinically indicated.  Patients who cannot be monitored should not be treated with ezogabine.  The ophthalmologic monitoring program should include visual acuity testing, dilated fundus photography, and optical coherence tomography.  Additional testing may include fluorescein angiograms, perimetry, and electroretinograms.  If retinal pigmentary abnormalities or vision changes are detected, ezogabine should be discontinued unless no other suitable treatment options are available and the benefits of treatment outweigh the potential risk of vision loss.', '2', '"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50861, 0, 'Ezogabine', 'Urinary Retention', 'The use of ezogabine may cause urinary retention.  A comprehensive evaluation of urologic symptoms should be conducted prior to and during treatment with ezogabine as clinically indicated.  It is recommended to monitor closely for urologic symptoms in patients at risk.', '2', '"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50862, 4450, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50863, 12215, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50864, 18486, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50865, 18617, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50866, 18618, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50867, 18619, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50868, 18620, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50869, 18621, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50870, 19524, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50871, 21635, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50872, 21636, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50873, 4450, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50874, 12215, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50875, 18486, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50876, 18617, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50877, 18618, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50878, 18619, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50879, 18620, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50880, 18621, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50881, 19524, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50882, 21635, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50883, 21636, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'Niederle N  Ostermann J  Achterrath W  Lenaz L  Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung  cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991):  59-62|Lokich J  Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-  day infusion." Cancer Treat Rep 65 (1981):  887-9|DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993):  a4491993|Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994):  s64-8|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50884, 4450, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50885, 12215, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50886, 18486, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50887, 18617, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50888, 18618, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50889, 18619, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50890, 18620, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50891, 18621, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50892, 19524, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50893, 21635, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50894, 21636, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50895, 2521, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50896, 16268, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50897, 16274, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50898, 18760, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50899, 18761, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50900, 22080, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50901, 29905, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50902, 29906, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50903, 2521, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10  the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50904, 16268, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10  the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50905, 16274, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10  the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50906, 18760, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10  the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50907, 18761, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10  the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50908, 22080, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10  the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50909, 29905, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10  the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50910, 29906, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10  the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50911, 2521, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50912, 16268, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50913, 16274, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50914, 18760, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50915, 18761, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50916, 22080, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50917, 29905, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50918, 29906, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', '"Product Information. Zetia (ezetimibe)." Schering-Plough Corporation  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50919, 0, 'Factor XIII (human)', 'Thromboembolism', 'Thromboembolic complications have been reported after therapy with factor XIII, particularly in patients with risk factors for thrombosis.  Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.', '2', '"Product Information. Corifact (factor XIII)." CSL Behring LLC  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50920, 0, 'Factor IX Complex (Human)', 'Thromboembolism', 'The use of factor IX complex concentrates has been associated with the development of thromboembolic complications.  Patients at increased risk for thrombosis include those undergoing surgery, post surgery, with known liver disease, and with signs of fibrinolysis, thrombosis, or disseminated intravascular coagulation.  When administering factor IX complex to these high-risk patients, monitor for early signs of consumptive coagulopathy with appropriate laboratory testing.  Only administer factor IX complex to patients when the benefits outweigh the risks.', '3', '"Product Information. Konyne 80 (factor IX complex)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50921, 0, 'Aminoglutethimide', 'Adrenal Insufficiency', 'Aminoglutethimide suppresses adrenal function and is indicated for the treatment of selected cases of Cushing''s syndrome.  It generally should not be used in patients with adrenocortical insufficiency.', '3', 'Box M, Saltissi D, Fawcett D "Inappropriate secretion of antidiuretic hormone following aminoglutethimide therapy." Br J Urol 58 (1986):  724-5|Bonneterre J, Nguyen M, Hecquet B, Cappelaere P "Aminoglutethimide-induced hypercholesterolaemia ." Lancet 1 (1984):  912-3|Davies JP, Bentley P, Ghose RR "Aminoglutethimide-induced hyperkalaemia." Br J Clin Pract 43 (1989):  263-4|Bork E, Hansen M "Severe hyponatremia following simultaneous administration of aminoglutethimide and diuretics." Cancer Treat Rep 70 (1986):  689-90|Santen RJ, Misbin RI "Aminoglutethimide: review of pharmacology and clinical use." Pharmacotherapy 1 (1981):  95-120|"Product Information. Cytadren (aminoglutethimide)." Ciba Self-Medication Inc  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50922, 0, 'Fenfluramine', 'Heart Diseases', 'Serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine have been associated with valvular heart disease.  Exercise care when using this agent in patients with cardiac disease.  Cardiac monitoring is required prior to starting, during, and after treatment.  If valvular heart disease is observed on an echocardiogram, the prescriber must consider the benefits versus the risks of initiating or continuing treatment.  Echocardiograms should be repeated every six months, and once 3-6 months posttreatment.', '3', '"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50923, 0, 'Fenfluramine', 'Lung Diseases', 'Serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine, have been associated with pulmonary arterial hypertension.  Exercise care when using this agent in patients with pulmonary disease.  Cardiac monitoring is required before starting, during, and after treatment.  Cardiac monitoring via echocardiogram can identify evidence of pulmonary arterial hypertension.  If pulmonary arterial hypertension is observed on an echocardiogram, the prescriber must consider the benefits versus the risks of initiating or continuing treatment.  Echocardiograms should be repeated every six months, and once 3-6 months posttreatment.', '3', '"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50924, 0, 'Fenfluramine', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50925, 0, 'Fenfluramine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50926, 0, 'Fenfluramine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50927, 0, 'Fenfluramine', 'Alcoholism', 'Fenfluramine can cause somnolence, sedation, and lethargy.  Central nervous system depressants, including alcohol, could potentiate these effects.  Exercise caution when using this agent in alcoholic patients or those at risk of sedation.  Close monitoring is advised.  Advise patients not to drive or operate machinery until they know how this drug will affect them.', '2', '"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50928, 0, 'Fenfluramine', 'Anorexia', 'Fenfluramine can cause decreases in appetite and weight.  Exercise care when using this agent in patients at risk of decreased appetite or weight.  It is recommended to monitor the growth of pediatric patients carefully.  Weight should be monitored regularly during treatment, and dose modifications should be considered if a decrease in weight is observed.', '2', '"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50929, 0, 'Fenfluramine', 'Hypertension', 'Fenfluramine can cause an increase in blood pressure.  Exercise care when using this agent in hypertensive patients.  It is recommended to monitor blood pressure in patients treated with fenfluramine.', '2', '"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50930, 0, 'Fenfluramine', 'Liver Failure', 'Fenfluramine is primarily metabolized to norfenfluramine by CYP450 1A2, CYP450 2B6, and CYP450 2D6.  The use of fenfluramine in patients with hepatic impairment is not recommended.', '2', '"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50931, 0, 'Fenfluramine', 'Kidney Diseases', 'Most of an orally administered dose of fenfluramine (greater than 90%) is excreted in the urine as fenfluramine, norfenfluramine, or other metabolites.  The use of fenfluramine in patients with moderate or severe renal impairment is not recommended.', '2', '"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50932, 0, 'Fenfluramine', 'Vision Disorders', 'Fenfluramine can cause mydriasis and can precipitate angle-closure glaucoma.  Exercise care when using this agent in patients with visual disturbances.  Consider discontinuing treatment in patients with acute decrease in visual acuity or ocular pain.', '2', '"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50933, 727, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50934, 4751, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50935, 4752, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50936, 7996, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50937, 11962, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50938, 12664, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50939, 12665, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50940, 17824, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50941, 17825, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50942, 18099, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50943, 18890, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50944, 18892, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50945, 19827, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50946, 20026, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50947, 20027, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50948, 27484, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50949, 27485, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50950, 27486, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50951, 28793, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50952, 28794, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50953, 28843, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50954, 28844, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50955, 29713, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50956, 29714, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50957, 29715, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50958, 30137, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50959, 30613, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50960, 30614, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50961, 31533, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50962, 32311, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50963, 727, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50964, 4751, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50965, 4752, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50966, 7996, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50967, 11962, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50968, 12664, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50969, 12665, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50970, 17824, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50971, 17825, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50972, 18099, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50973, 18890, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50974, 18892, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50975, 19827, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50976, 20026, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50977, 20027, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50978, 27484, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50979, 27485, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50980, 27486, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50981, 28793, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50982, 28794, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50983, 28843, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50984, 28844, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50985, 29713, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50986, 29714, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50987, 29715, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50988, 30137, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50989, 30613, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50990, 30614, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50991, 31533, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50992, 32311, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):|"Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50993, 727, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50994, 4751, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50995, 4752, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50996, 7996, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50997, 11962, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50998, 12664, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50999, 12665, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (51000, 17824, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', '"Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
